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Placental syncytiotrophoblast microvesicles (STBM) are biologically active, membrane-
bound, subcellular vesicles shed into maternal circulation during pregnancy as a normal 
turnover of the placental surface. Quantitative and possibly qualitative STBM changes 
take place in adverse pregnancy outcomes such as pre-eclampsia (PE). However, the 
role of STBM in recurrent miscarriage (RM) remains insufficiently explored.  
The objective of this study is to evaluate the immunogenicity of STBM in women with 
RM. Women with PE were studied as a comparison group. Study hypotheses are: i) 
STBM stimulate antigen presenting cells (APCs), such as dendritic cells (DCs) & 
macrophages, more in disease compared to health; ii) STBM bioactive contents, e.g. 
proteins and lipids, differ in disease and health; and  iii) decidual DCs at maternal-foetal 
interface differ in disease and health. 
Placentas from patients with a history of PE (n=13) or RM (>2 consecutive losses, <20 
weeks) (n=22) and gestational age-matched normal controls were collected at the time 
of delivery or loss. STBM were generated using placental explant culture and then used 
in DC and macrophage stimulation assays as well as in mixed leukocyte reactions 
(MLR). Immune response was characterized by detecting cytokine secretion and 
changes in surface phenotype. Microvesicle bioactive contents were investigated by 
mass-spectrometry (ESI LC-MS/MS) of proteins and lipids. Decidual dendritic cell 
subsets were studied by a 13-colour flow cytometry. 
The results show that STBM from RM and PE patients were more immunogenic as 
evidenced by significantly increased production of pro-inflammatory cytokines such as 
  ix
IL-6 and TNF-α from stimulated DCs and macrophages, compared to the normal 
controls. STBM proteins include alarmins (heat shock proteins and fibronectin), stress 
and immune-regulatory molecules (annexins, integrins, and peroxiredoxins), 
complement and complement regulatory molecules (C1q, C3, C4, CD46, CD55, CD59 
and vitronectin), lipid metabolism regulatory molecules (apolipoproteins A, and E) and 
transcriptional-regulatory molecules (histones). Among these, 14 proteins were found to 
be differentially expressed in adverse pregnancies compared to healthy pregnant 
controls.  
Lipidomic analysis revealed that the major lipid classes in STBM are sphingomyelin 
(SM), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidic acid (PA) and 
phosphatidylinositol (PI). SM/PC ratio showed a unique reversal (3:1) compared to that 
normally found in human cells. PS was upregulated and PI, PA and GM3 was 
downregulated in adverse pregnancies compared to healthy pregnant controls.  
Three myeloid DC subsets could be identified in human decidua: i) CD14+ DCs; ii) 
CD11c+ DCs; and iii) CD141hi DCs. One particular patient with 5 previous miscarriages 
demonstrated a markedly higher frequency of CD141hi DCs (1.48% of CD45+ cells), 
compared to the other RM (0.2%) and the normal controls (0.2%). 
Increased immunogenicity of STBM, as well as differential expressions of STBM proteins 
and lipids that are implicated in inflammation, coagulation, oxidative stress, apoptosis 
and immune response, suggest their pathophysiologic relevance in RM and PE. 
Presence of the most efficient antigen presenting cell CD141hi DCs in decidua may have 
implications in the immune dysregulation of RM.  
  x
Collectively, the findings of this study lend support to the emerging concept of immune-
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 Figure 3.1 Representative images of STBM basic characterization. A. Light  
  microscopy of villous explants with H/E staining of villous   
             explants showing deep blue syncytiotrophoblast (STB) layer at  
  periphery; B. Immunofluorescence (IF) image of villous explants  
  demonstrating the bright green layer of STB stained for PLAP  
  protein; C. Morphology of STBM by scanning electron microscopy;   
             D. PLAP expression of STBM by flow cytometry; E. TaqMan PCR  
             of STBM DNA; F. Nanoparticle tracking analysis of STBM. 
Figure 3.2 Representative confocal images of dendritic cells after being  
  incubated with (top panel) or without (bottom panel) 100 µg/ml  
  STBM for 24 hr. Monocyte-derived dendritic cells showing, (A)  
  brightfield image; (B) CD11c (red); (C) STBM (green); (D) overlay; 
  (E) single monocyte-derived dendritic cell with 3-D image; DC left  
  unstimulated showing (F) brightfield image; (G) CD11c (red); (H)  
  no green fluorescence in green filter. Bar represents 20 µm. 
Figure 3.3 Representative forward scatter/side scatter (FSC/SSC) dot plots of 
  DC, left unstimulated or incubated with indicated preparation of  
  100 µg/ml STBM or 500 ng/ml LPS for 24 hr. 
Figure  3.4 Surface phenotype of unstimulated (immature) and LPS-stimulated 
  (mature) DC. DCs differentiated from monocytes after 6 days of  
  culture were considered immature DC. Harvested cells were left  
  unstimulated or stimulated with LPS (500 ng/ml) for 24 hrs to allow 
  maturation. CD40, CD80, CD83, CD86, MHC I, MHC II and CCR7  
  antibodies were used to stain the DC. Filled histograms are signals 
  obtained with isotype IgG. Open histograms are staining with  
  specific antibodies. 
Figure 3.5 Surface phenotype of DC stimulated by STBM from woman with  
  RM and gestational age matched normal control. DCs were  
  stimulated with STBM for 24 hrs. Filled histograms are signals  
  obtained with isotype IgG. Open histograms are staining with  
  specific antibodies, red histograms, RM STBM; blue histograms,  
  normal control STBM. 
Figure 3.6        Surface phenotype of DCs stimulated by STBM from woman with  
  PE and gestational age matched normal control. DCs were  
  stimulated with STBM for 24 hrs. Filled histograms are signals  
  obtained with isotype IgG. Open histograms are staining with  
  specific antibodies, red histograms, PET STBM; blue histograms,  
  normal control STBM. 
Figure 3.7 Normal STBM-mediated dose-dependent secretion of cytokines by 
  monocyte-derived dendritic cells. Cells were left untreated or co- 


























  representative of at least 2 independent experiments. 
Figure 3.8 RM (non-live births) - proinflammatory cytokine release    by 
             DCs. DCs (7 X 104 per well) were stimulated for 24 hr with   
  placental STBM from patient & gestational age matched normal  
  healthy control (n=2), LPS (positive control) or left unstimulated  
  (negative control). Cytokine production was determined by ELISA. 
  All experiments were performed in triplicates with at least 2  
  independent experiments carried with the same batch of samples,  
  Results are expressed as mean values of experimental triplicates  
  ±SEM. Histopathology of placenta shows massive perivillous  
  fibrinoid deposition. 
Figure 3.9 Severe pre-eclampsia requiring termination- significant   
  proinflammatory cytokine release by DCs. DCs were stimulated  
  with placental STBM from patient & gestational age matched  
  normal healthy control (n=2), LPS (positive control) or left   
  unstimulated (negative control). Results are expressed as mean  
  values of experimental triplicates ±SEM.  Histopathology of  
  placenta shows marked villous ischaemia, villi are thin and slender 
  with widening of intervillous space. 
Figure 3.10 RM (live birth) - significantly increased proinflammatory cytokine  
  release by Dendritic cells & T cells. DCs were stimulated with  
  placental STBM from patients & gestational age matched normal  
  healthy controls (n=20), LPS (positive control) or left unstimulated  
  (negative control). Results are expressed as mean values of  
  experimental triplicates ±SEM. Section show placental tissue with  
  focal congestion, prominent is tissue knobs and scattered   
  intervillus fibrin deposition. No infarct is noted. No fibrin thrombi  
  identified. A few inflammatory cells composed of lymphocytes and  
  a few neutrophils are seen in the decidua. 
Figure 3.11 PE (live birth)- significantly increased proinflammatory cytokine  
  release by Dendritic cells & T cells. DCs were stimulated with  
  placental STBM from patients & gestational age matched normal  
  healthy controls (n=11), LPS (positive control) or left unstimulated  
  (negative control). Results are expressed as mean values of  
  experimental triplicates ±SEM.  Histopathology of placenta does  
  not show evidence of marked ischaemia, thrombosis or infarction. 
Figure 4.1 Representative 1D SDS PAGE Gel Images of PE and RM-STBM 
proteins; (a) Lane 1: molecular weight marker. Lanes 2, 3 & 4: 
Normal STBM. Lanes 5, 6 & 7: PE STBM. Loading volume: 20 uL 
per lane (~50 ug of proteins); (b) Representative 1-D SDS PAGE 
gel images of protein extracts from STBM. Lane 1: molecular 
weight marker. Lanes 2 & 3: RM STBM. Lanes 4 & 5: Normal 
STBMs. Loading volume: 20 uL per lane (~50 ug of proteins).  



























Figure 4.3 GO analysis of cellular components of STBM proteins 
 
Figure 4.4 GO analysis of molecular functions of STBM proteins 
 
Figure 4.5 Representative images of Immunohistochemical validation of mass 
spectrometry-based STBM proteomic data in placental villous 
tissues. There was a trend towards decrease in the studied protein 
expressions in PE and RM placental villi. Proteins are localized in 
the trophoblasts. Bars represent 100 µm (X20).    
 
Figure 4.6 Representative images of Immunohistochemical validation of mass 
spectrometry-based STBM proteomic data in placental villous 
tissues. There was a trend towards decrease in the studied protein 
expressions in PE and RM placental villi. Proteins are localized in 
the trophoblasts. Bars represent 100 µm (X20).    
 
Figure 4.7: Representative images of Immunohistochemical validation of mass 
spectrometry-based STBM proteomic data in placental villous 
tissues. There was a trend towards decrease in the studied protein 
expressions in PE and RM placental villi. Proteins are localized in 
the trophoblasts. Bars represent 100 µm (X20). 
 
Figure 4.8: Representative images of negative controls of PE & RM placentas  
 
Figure 4.9 Summary of Immunohistochemistry analysis of placenta of PE and 
RM patients (a) PE-STBM protein expressions; (b) RM-STBM 
protein expressions 
 
Figure 5.1   Chemical structure of various STBM polar lipids 
 
Figure 5.2  Lipid composition of RM STBM. Comparison of mean molar 
fractions of phospholipids and sphingolipids classes in STBM from 
RM patients (n=9) and normal pregnant women (n=9). 
 
Figure 5.3  Lipid composition of Active RM STBM. Comparison of mean molar 
fractions of phospholipids and sphingolipids classes in STBM from 
RM patient with ongoing loss (n=1) and normal pregnant women 
(n=1). 
 
Figure 5.4  Lipid composition of PE STBM. Comparison of mean molar 
fractions of phospholipids and sphingolipids classes in STBM from 
PE patients (n=6) and normal pregnant women (n=6). 
 
Figure 5.5 Major Lipid Classes in PE & RM STBM. Comparison of total molar 
fractions of phospholipids and sphingolipids classes in STBM from 
PE (n=6) & RM patients (n=9) and normal pregnant women. * p 
<0.05. 
 
Figure 5.6 Major Lipid Species within each class in PE STBM. Comparison of 
mean molar fractions of individual phospholipids and sphingolipids 


























women (n=6). * p <0.05. 
 
Figure 5.7 Major Lipid Species within each class in RM STBM. Comparison of 
mean molar fractions of individual phospholipids and sphingolipids 
species in STBM from RM patients (n=9) and normal pregnant 
women (n=9). * p <0.05. 
 
 
Figure6.1(A-D)Identification of CD141hi DCs in Human Tissues. Flow cytometry of 
peripheral blood, collagenase-treated whole skin, liver, and 
mechanically dispersed lung. Gating strategy used to identify three 
myeloid DC subsets within Lin-HLA-DR+ fraction (yellow gate) in 
tissues: (1) CD14+ DCs (blue gate), (2) CD14-CD11c+ DCs (green 
gate), and (3) CD14-CD11cloCD141hi DCs (red gate). 
 
 
Figure 6.1 (E) Frequency of CD14+ DC, CD11c+ DC and CD141hi DC in blood, 
liver and skin as a % of CD45+ mononuclear cells. Scatterplot from 
6 donors are shown. *p < 0.05, Mann-Whitney U test. 
 
Figure 6.1(F) Morphology of FACS-sorted blood and skin CD141+, CD1c+, and 
CD14+ DCs and monocytes. (upper panel) visualized by GIEMSA 
staining of cytospin preparations (X100) and (lower panel) by SEM. 
Scale bars represent 10 mm in (upper panel) and 1 mm in (lower 
panel). 
Figure 6.2(A-D) Flow-cytometry gating strategy for (A) blood from RM patients,  
  (B) collagenase-digested decidua from RM patients, (C) blood from 
  normal pregnant controls (D) collagenase-digested decidua from  
  normal pregnant controls. Decidua samples were analyzed using  
  the same flow strategy to map known blood DC subsets to   
  peripheral tissue populations (Haniffa et al., 2012). Cells were first 
  gated by FSC-A and SSC-A and dead cells were excluded by  
  DAPI staining. Leukocytes were identified using CD45 followed by 
  exclusion of doublets using the SSC-A and SSC-W. Antigen  
  Presenting Cells (APC) were identified within the HLA-DR+ and  
  Lineage- (CD3, CD19, CD20 and CD56 all in FITC) fraction.  
  Having the Lineage cocktail in the FITC channel also allowed us to 
  exclude autofluorescent macrophages in peripheral tissues. Three 
  myeloid DC subsets can be identified in human decidua:1. CD14+  
  DCs corresponding to blood CD14+ monocytes; 2. CD11c+ DCs  
  corresponding to blood CD11c+ DCs; and 3. CD141hi DCs   
             corresponding to CD141hi blood DCs. CD11c-CD141- cells are  
  comprised of CD123+ plasmacytoid DCs (pDCs) and CD34+  
  haematopoietic progenitor cells in the blood. 
 
Figure 6.3 Frequency of DC subsets in decidua & blood as a % of CD45+ 
mononuclear cells. Scatterplot from 2 recurrent miscarriages (RM) 



























shown. Lines represent the median. Results are combined data 
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Chapter 1: Introduction 
 
1.1     Microvesicles 
1.1.1  Definition 
 
Microvesicles are biologically active membrane-bound, sub-cellular elements produced 
during apoptosis, cellular activation or by vesicle secretion. These have been long 
viewed as artifacts or inert cellular debris. However, recent intense research interest in 
the pathophysiological relevance of microvesicles in autoimmune, cardiovascular, 
thromboembolic and inflammatory disorders has revealed the contrary. Current 
evidence recognizes their novel role as modulators of intercellular communication and 
immune function (Morelli etal., 2006, Schiller et al., 2008).  
 
Microvesicles are nano-sized (<1µm) membrane fragments released into extracellular 
matrix by various healthy and diseased cells (Debski et al., 1991, Thery et al., 2002, 
Redmanet al., 2008, Lok et al., 2008, Cocucci et al., 2009, Redman et al., 2011). They 
are sealed by cell membrane lipid bilayer and may contain bioactive materials such as 
diverse membrane and cytosolic proteins, lipids, signaling molecules, DNA, 
messenger and microRNAs (Southcombe et al., 2011).  There are three main types of 
sub-cellular vesicles: i) vesicles that bud directly from the cell membrane, ii) exosomes 
that were generated from multivesicular bodies within the cell, and iii) apoptotic bodies 
(ABs) that are small sealed membrane vesicles generated by cells undergoing cell 




 1.1.2  Biogenesis and shedding of microvesicles 
 
Microvesicles are found commonly in cell cultures in vitro and in body fluids in vivo. 
The shedding process of microvesicles is stimulated by various events including 
inflammatory stimuli or calcium influx. The process is calpain-dependent (Yano et al, 
1993). Examples of inflammatory stimuli facilitating shedding include cytokines such as 
TNF-α or IL-1β, or laboratory agents such as phorbol ester, ionomycin, Phorbol-12-
myristate-13-acetate (PMA), concanavalin A, or activated complement C5a (Distler et 
al., 2005).  Calcium chelation inhibits microvesicle generation. Increased cytosolic 
calcium activates various cytosolic enzymes relevant to microvesicle formation 
including calpain, facilitating breakdown of cytoskeleton, activation of apoptosis, and 
shedding of membrane blebs. The nature of stimulus may determine the type of 
vesicles generated. Microvesicles are released from viable cells during activation or 
dying cells during apoptosis by shedding or direct blebbing of the plasma membrane in 
a regulated way. They range in size between 0.1 to 1 µm (Figure 1.1). Exosomes or 
nanovesicles are, however, secreted via exocytosis from intracellular multivesicular 
bodies of the endosome and are much smaller in size (30-100 nm). Apoptotic bodies 
(500 nm-3 µm in diameter) are released by cells undergoing apoptosis by separation 




Figure 1.1: Generation of shedding vesicles. Reproduced from Coccucci et al., 2009. 
 
Endosomes produced at plasma membrane fuse to form endocytic cisternae and 
subsequently multivesicular bodies (MVB) containing numerous 30-100 nm vesicles. 
There are two types of MVBs; the degradative MVBs that evolve into lysosomes and 
the exocytic MVBs that fuse their membrane with plasma membrane upon cell 
stimulation or activation leading to secretion and exposition of their internal vesicles 
known as exosomes (Murk et al., 2002) (Figure 1.2). 
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Figure 1.2: Generation of exosomes. Reproduced from Coccucci et al., 2009. 
 
Apoptosis is a highly regulated and energy-dependent process culminating in 
formation of sealed sub-cellular fragments termed apoptotic bodies (AB) (Cotter et al., 
1990) (Figure 1.3). Their formation and rapid engulfment by environmental phagocytes 
ensure a regulated, anti-inflammatory clearance of apoptotic debris under 
physiological conditions. If energy depletion occurs during the cascade of apoptosis, 
the process of cell death deviates to the energy-independent cellular breakdown 
termed secondary necrosis (Nicotera et al., 2000). An incomplete execution of the 
apoptosis program followed by degeneration and necrosis has been termed 
aponecrosis (Formigli et al., 2000). Necrotic debris may lead to a pro-inflammatory 
response in pathological conditions.  
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 Figure 1.3: Transmission Electron Microscopy of ABs showing membrane-coated 
vesicles, 500 nm in size. Bar represents 100 nm. Reproduced from Schiller et al., 
2008.  
 
1.1.3  Bioactive contents of microvesicles 
During apoptosis or activation, cellular components are packed within membrane 
vesicles or blebs and antigens are relocalised towards the surface of the cells (Radic et 
al., 2004, Frisoni et al., 2005). Thus, microvesicles seem to be mediators of intercellular 
communication by virtue of their bioactive contents such as diverse membrane and 
cytosolic proteins, lipids, nuclear proteins, nucleic acids including messenger and 
microRNAs, and signaling molecules from the cells of origin.   
Protein composition 
Proteomes of microvesicles or exosomes isolated from human platelets, plasma, 
malignant lymphocytes, B cells, dendritic cells, mast cells, and intestinal epithelial cells 
have been described (Garcia et al., 2005, Jin et al., 2005, Smalley et al., 2007, Little et 
al., 2010, Miguet et al, 2006, Wubblots et al. 2003, Thery et al., 1999, Thery et al., 2001, 
Skokos et al., 2001, Van Niel et al., 2001). These proteins are broadly divided into two 
categories: i) ubiquitous proteins which are produced by almost all cells, and ii) cell-
specific proteins which are unique to the cells of origin. Exosomal proteins include 
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cytosolic, endosomal and membrane proteins. About 80% of exosomal proteins are 
conserved among species and characteristic protein families include tetraspannins 
(CD9, CD63, CD81 and CD82), heat shock proteins (HSP70, HSP90), 
structural/cytoskeletal proteins (tubulin, actin, actin binding proteins), metabolic 
enzymes, membrane transport and fusion proteins (annexins and RAB proteins), signal 
transduction proteins (protein kinases, 14-3-3, G proteins), integrins and MHC class I 
and II molecules (Thery et al., 2002). These ubiquitous proteins are most likely involved 
in exosome biogenesis (Figure 1.4).          
 
Figure 1.4: Schematic representation of exosomes produced by dendritic cells. 
Reproduced from Thery et al., 2002. 
Examples of cell-specific proteins include MHC class II in exosomes from all cells 
expressing MHC class II, CD 86 from DC-derived exosomes which is a co-stimulatory 
molecule for T cells, T-cell receptors for T-cell derived exosomes, immunoglobulin family 
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members (CD54 on B cells, P-selectin on platelets), etc.. In contrast to exosomes, 
microvesicles/apoptotic bodies released by apoptotic cells contain nuclear and 
organeller proteins, DNA, messenger and microRNA. Both exosomes and microvesicles 
are now considered  to provide unconventional routes of protein secretion (Nickel et al., 
2005).  
Lipid composition 
Current evidence on lipid composition of microvesicle population is limited so far. They 
are encapsulated by a lipid bilayer. A key early event in their mode of formation is 
reorganization of the lipid asymmetry of the plasma membrane with externalization of 
phosphatidylserine (PS) which is normally present on the cytosolic side of plasma 
membrane. Lipid rafts, which are the plasma-membrane microdomains, and their 
accompanying cholesterol and proteins are concentrated where the membrane buds. 
Therefore, microvesicles are enriched in raft associated lipids.  
Lipids have important roles as signaling molecules in various physiologic processes 
including immune response. There is increasing evidence suggesting that lipids in 
microvesicles can elicit cellular responses. For example, platelet-derived microvesicles 
treated with secretory phospholipase A2 have been shown to activate endothelial cells 
and cause platelet aggregation with arachidonic acid being the active principle (Barry, et 
al., 1997, 1998). Platelet or RBC-derived microvesicles treated with a combination of 
phospholipase A2 and sphingomyelinase cause platelet aggregation with 
lysophosphatidic acid being the active principle (Fourcade, et al., 1995). Endothelial cells 
exposed to peroxides, release microvesicles containing oxidized phospholipids and 
activate neutrophils (Patel et al., 1992). Apoptotic blebs and oxidized microvesicles have 
been shown to contain proinflammatory oxidized phospholipids that stimulate endothelial 
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cells to specifically bind with monocytes, initiating atherogenesis (Huber et al., 2002). 
Collectively this evidence on the bioactive content of microvesicles lends support to their 
emerging role as mediators of intercellular communication. 
1.1.4  Functions of microvesicles 
Microvesicles can influence physiology of their target cells by inducing intracellular 
signaling following binding to receptors or conferring new properties by transfer of 
bioactive materials such as lipids, cytokines and growth factors after fusion or 
endocytosis (Orozcoet al., 2010, Coccucci et al., 2009, Chaput & Thery, 2010, Thery 
2009). It has now become established that apoptotic blebbing and microvesicle release 
plays a significant role for the interaction of the parent cell and immune system resulting 
in immunomodulation (Thery et al., 2002). These vesicles may interact with surrounding 
cells or are engulfed by phagocytes or antigen presenting cells as macrophages, 
dendritic cells, and B cells which may lead to immunogenic presentation of antigen in an 
inflammatory context.  Facilitation of antigen presentation may lead either to a pro-
inflammatory or anti-inflammatory response, such as by exposure of FasL (CD95) and 
induction of apoptosis in Fas-bearing cells (Figure 1.5).  
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 Figure 1.5: Role of exosomes in immune response. Uptake of pathogens in the 
periphery leads to generation of peptide-MHC complexes by the immature or maturing 
dendritic cells (DCs) in the tissues (green). Some of these complexes could be secreted 
in exosomes. This would lead to sensitization of other DCs (blue) which are not exposed 
to the pathogen directly. Next, all these DCs migrate out of the tissue towards the 
draining lymph nodes. An exchange of exosomes between the newly arrived DCs and 
the resident ones could occur inside the lymph nodes. Thus exosome production would 
lead to increased number of DCs that bear the relevant peptide-MHC complex and 
subsequent amplification of the magnitude of immune response. In the absence of 
inflammation, spontaneous migration of exosome-bearing DCs could lead to tolerance 
induction. Reproduced from Thery et al., 2002. 
Microvesicles also participate in physiological processes including hemostasis and 
thrombosis by exposing binding sites for activated coagulation factors and tissue factor, 
the initiator of coagulation in vivo (Nieuwland et al., 2000, Biro et al., 2003), inflammation 
(Berckmans et al., 2005), angiogenesis (Kim et al., 2004), vasoconstriction (Boulanger et 
al., 2001), immune modulation (Peche et al., 2003, Taylor et al., 2006) and endothelial 
dysfunction (Vanwijk et al., 2002). Their circulating levels, cellular origin, composition 
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and function have been shown to be altered in various pathological conditions including 
atherosclerosis and coronary artery disease, pre-eclampsia, hematological and 
inflammatory diseases, diabetes and malignancies. However, it is unclear whether these 
changes cause disease development or are a consequence of the disease process 
itself. 
1.2     Pregnancy-Associated Microvesicles 
1.2.1  Microvesicles in normal pregnancy 
Microvesicles present in plasma of pregnant women originate from blood cells, 
endothelial cells and the placenta (Figure 1.6).  
 
Figure 1.6: Microvesicles in pregnancy and the processes thought to be affected by 
these vesicles in health and disease. Reproduced from Toth et al., 2007. 
The most abundant microvesicles in pregnancy are platelet-derived. Compared to non-
pregnant women, increased levels of microvesicles occur in pregnant women (Knight et 
al., 1998). It is recognized that normal pregnancy is a pro-inflammatory and pro-
coagulable condition. Hence the activations of leukocytes and platelets are expected to 
contribute to this increase in microvesicle population. The presence of placenta-derived 
syncytiotrophoblast microvesicle (STBM) is unique to pregnancy (Figure 1.7a)                       
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Figure 1.7: (a). Deficient placentation, placental hypoxia & generation of STBM in pre-
eclampsia. Reproduced from van der Post et al., 2011. (b). Schematic presentation of 
known immune & vascular effects of trophoblast debris. Reproduced from Askelund et 
al., 2011. 
STBM are shed from placenta into maternal circulation as a result of the normal turnover 
and renewal of placental surface and thus they interact with circulating maternal immune 
cells and endothelial cells (Figure 1.7b) (Askelund et al., 2011). STBM constitutes 1.5- 
3% of the total microvesicle population in a healthy pregnancy and 2.2-6% in pre-
eclamptic pregnancy (Lok et al., 2008). During normal pregnancy, STBM are taken up 
and cleared by monocytes and dendritic cells, resulting in the production of 
proinflammatory cytokines such as TNF-α, IL-12 as well as marginal levels of IL-18 and 
IFN-γ. STBM are also considered physiologically relevant in establishing tolerance at 
feto-maternal interphase by transporting immunomodulatory bio-molecules from parent 
syncytiotrophoblast cells such as HLA-G, FasL, TRAIL, IDO, and complement inhibitors 
(CD46, CD55, CD59). This contributes to the suppression of Th1 responses observed in 
successful pregnancy. These mechanisms are employed to protect the fetal allograft and 
allow it to evade detection by paternally-inherited fetal antigen recognizing maternal T 
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cells. STBM concentration increases with advancement in gestation as the placenta size 
increases to support the growing fetus.  
                     
Figure 1.8: Ultra structure of normal and preeclamptic syncytial surface (tissue fixed 
immediately after delivery). (A) Normal syncytium showing normal microvilli on apical 
surface (B) Syncytium in severe preeclampsia showing distorted microvilli and shedding 
of debris, such as, A. apoptotic bodies (1µm), B. microvesicles (100nm-1µm), C. 
exosomes (70nm-120nm), Reproduced from Redman et al., 2011. 
1.2.2  Microvesicles in adverse pregnancy outcomes 
In adverse pregnancy outcomes such as pre-eclampsia, recurrent miscarriages with or 
without association with autoimmune antibodies, premature labour, there is 
dysregulation of immunomodulation, inflammation, endothelial dysfunction and 
thrombosis. STBM shedding may undergo changes in these pregnancy complications 
(Figures 1.8A & 1.8B). The numbers of total and platelet-derived microvesicles are 
decreased in preeclampsia (PE), however the number of P-selectin exposing platelet-
derived microvesicle is increased (Lok et al., 2008, Brettle et al., 2003) reflecting platelet 
activation (Lok et al., 2007, Maccy et al., 2010). Elevated level of erythrocyte-derived 
microvesicles has been found in PE as a result of haemolysis and/or 
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haemoconcentration (Lok at al., 2008). In PE, elevated numbers of microvesicles 
derived from T cells, monocytes and granulocytes have also been reported reflecting 
granulocyte activation (Meziani et al., 2006, van Wijk et al., 2002, Lok et al., 2009). 
Some authors have reported elevated numbers of endothelial cell-derived microvesicles 
(Gonzalez-Quintero et al., 2003, 2004). Plasma samples from PE patients have shown 
increased levels of STBM compared to normal pregnancy controls and this is thought to 
result from placental hypoperfusion and increased trophoblast apoptosis and shedding. 
Paternal genes are expressed preferentially in the syncytiotrophoblast and immune 
tolerance towards the fetus requires specific and sufficient suppression and adaptation 
of maternal immune system. Maternal maladaption to the fetal allograft may lead to 
increased trophoblast apoptosis and shallow trophoblast invasion resulting in incomplete 
substitution of maternal spiral arterial endothelium. Resulting deficient spiral artery 
remodeling, insufficient placentation and placental hypoperfusion leads to ischaemia-
perfusion injury and oxidative stress. This probably culminates into increased trophoblast 
shedding and raised STBM level in maternal plasma (2-6% in PE vs 1-3% in normal 
healthy pregnancy) (Knight et al., 1998, Redman et al., 2007, Redman et al., 2008). Lok 
et al showed a decrease in total plasma microparticles (MP) and a statistically 
insignificant increase in STBM level in PE (Lok et al., 2008) (Table 1). However, the 
authors reported significant increases in STBM level in some of the preeclamptic 
patients who did not distinguish themselves clinically from the other patients. 
Interestingly, in a separate study, statistically significant increase in STBM level was 
found only in the case of early-onset PE, <34 weeks of gestational age (Figure 1.9) 
(Goswami et al., 2006). 
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Table 1.1. Cellular origin of circulating microparticles (MP) in pre-eclampsia .Reproduced 
from Lok et al., 2008.  
  
Figure 1.9: Peripheral venous blood concentrations of STBM (NDOG2) in women with 
early-onset pre-eclampsia (EOPET; open triangles- birth weight <5th percentile for 
gestational age), late-onset pre-eclampsia (LOPET; open triangles- birth weight <5th 
percentile for gestational age), normotensive intrauterine growth restriction (nIUGR), 
normal pregnancy, and non-pregnancy (non-preg). Horizontal bars represent median 
values Non-pregnancy values significantly lower than all other pregnancy groups. MWu- 
Mann Whitney U  test, W- Wilcoxon test. Reproduced from Goswami et al., 2006. 
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While STBM in PE is a vibrant area of research, the role of STBM in RM remains yet 
unclear. 
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1.2.3  Functions of microvesicles in adverse pregnancy outcomes 
Circulating placental microvesicles have the potential to interact with various maternal 
immune cells. The cargo they carry may provide them with the capabilities to participate 
in various physiologic ((Figure 1.10) and pathogenic processes (Figure 1.11). Redman et 
al in their recent review on STBM have emphasized this based on their unpublished 
observations on STBM proteome (Redman et al., 2011, Tannetta et al., unpublished 
observations). Proinflammatory effects of STBM may be due to their expression of 
danger molecules such as Hsp 70 and HMGB1. Procoagulant activity may be due to 
their expression of tissue factor. Sflt-1 and endoglin expressed by STBM may contribute 
to endothelial dysfunction while FasL and MICA/B may be responsible for their 
immunosuppressive or immunoregulatory function regulating maternal NK cell or T cell 
responses. The expressions of all these proteins may alter in adverse pregnancies 
compared to normal pregnancies.                    
 
Figure 1.10: Functional activities of STBM and the relevant cargo they carry. 
Reproduced from Redman et al., 2011. 
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In a recent report, Rajakumar et al have shown that syncytial knots, shed from placental 
explants and loaded with sFlt1 protein and mRNA, are metabolically active and capable 
of de novo gene transcription and translation (Rajakumar et al., 2012). The authors 
speculated that these shedded particles represent an autonomous source of sFlt1 
delivery into maternal circulation. This process of microvesicle formation, shedding and 
appearance in maternal circulation may be a novel mean by which sFlt1 and other toxic 
proteins such as soluble endoglin may be delivered systemically into maternal 
circulation. This may subsequently mediate the major events of adverse pregnancy 
outcomes such as PE. Thus, STBM may contribute to the pathogenesis of adverse 
pregnancy outcomes such as PE and RM. 
Vascular response 
Cell-derived microvesicles modulate the several cellular responses in vitro as well as in 
vivo (Figure 1.10 & 1.11). Plasma microvesicle samples from PE patients, but not from 
normal pregnant controls, impair vascular dilatation of myometrial arteries in vitro 
(Vanwijk et al., 2002). Also microvesicles from PE patients induced increased nitric oxide 
production associated-vascular hyporeactivity of human omental arteries and mouse 
aortas (Meziani et al., 2006). The proliferation of endothelial cells is inhibited and 
endothelial cell monolayer is disrupted in the presence of STBM (Gupta et al., 2005, 
Kertesz et al., 2000, Smarason et al., 1993). However, expression of inflammation-
related genes in endothelial cells was found not to be affected by pre-eclamptic 
microvesicles or STBM (Lok et al., 2006). Nevertheless, supernatants from co-cultured 
endothelial cells and STBM activated peripheral blood leukocytes such as granulocytes, 
monocytes and lymphocytes, in vitro (von Dadelszen et al., 1999).  This evidence 
suggests that factors released from endothelial cells in presence of diseased STBM can 
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indeed affect various cellular responses and thus may play a substantial role in 
pathogenesis of PE.  
A subgroup of women with RM with increased number of procoagulant microvesicles 
even in non-pregnant state are thought to be in permanent prothrombotic state. These 
micorvesicles, originated from endothelial cells (Carp et al., 2004), as well as blood cells 
(Laude et al., 2001), expose phosphatidylserine (PS) and are believed to induce 
coagulation (Vanwijk et al., 2003). Microparticles also lead to increased expression of 
adhesion molecules (Barry et al., 1997; Mesri and Altieri, 1998), thus amplifying the 
procoagulant and/or inflammatory response on the endothelial cell surface. The 
presence of endothelial and blood cellular  microparticles in the interval between 
pregnancies may be a chronic state of blood vessel and blood cellular activation which 
only becomes apparent in pregnancy. 
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The evidence suggests that pregnancy loss may be related to vascular endothelial cell 
activation.                                   
 
Figure 1.11: Functions of circulating microvesicles in pre-eclampsia . The microvesicles 
interact with leukocytes (L), monocytes (M) and endothelial cells (EC), thus affecting 




There is an exaggeration of the procoagulant and proinflammatory state of normal 
pregnancy in PE. Microvesicles may contribute to coagulation by providing a membrane 
surface for activated coagulation factors to bind and by exposing tissue factor (TF), the 
initiator of blood coagulation. The increased level of plasma coagulation activation 
markers in pregnancy is further increased in PE and so is the TF activity expressed by 
STBM shed from preeclamptic placenta (Vanwijk et al., 2002, Gardiner et al., 2011). In 
RM, increased fibrin deposits are present in intervillus spaces of the placenta suggesting 
RM may be secondary to an exaggerated haemostatic response of pregnancy (Dolitzky 
et al., 2006, Rai et al., 2003). This hypercoagulability may be attributed to other 
procoagulant factors including microvesicles and exosomes (Vanwijk et al., 2003). 
Coagulation-promoting capacity of circulating microvesicles, based on a prothrombinase 
assay, in women with RM were found to be increased compared to the non-pregnant 
controls, and was more pronounced among patients with early losses (gestational 
age<10 weeks) (Laude et al., 2001). In pregnant mice, injection of artificially prepared 
procoagulant phospholipid vesicles containing phosphatidylserine induced thrombosis in 
the placental bed and led to reduced birth weight (Sugimura et al., 1999). Thus, the 
presence of circulating procoagulant microvesicles in women with RM may be an 
acquired thrombophilia that becomes manifest during pregnancy when additional factors 
come into play promoting coagulation. However their precise role in the pathogenesis of 
adverse pregnancies remains unclear. 
25% of both coagulant and anticoagulant activities in blood are associated with platelet-
derived microvesicles. Platelet activation not only leads to an increase in its 
procoagulant phenotype but also its ability to inactivate factor Va by activating protein C 
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(Tans et al., 1991). PE it is known to be associated with a decrease in the total and 
platelet-derived microvesicle number (Lok et al., 2008). Resulting insufficient activation 
of protein C may lead to reduced inhibition of coagulation factors and a net increase in 
coagulation activation, i.e. both a quantitative and qualitative change in plasma 
microvesicles may be an inciting factor here. 
Inflammatory response 
STBM derived from normal placenta are immunogenic and induce secretion of 
proinflammatory cytokines such as TNF-α, IL-12p70 and IL-18 by PBMCs from healthy 
non-pregnant women, suggesting their potential contribution in the proinflammatory state 
of normal pregnancy and possibly PE (Germain et al., 2007). STBM from normal 
placenta have been shown to stimulate monocytes, upregulate their surface expression 
of ICAM-1 and induce them to release proinflammatory cytokines such as IL-8, IL-6 and 
IL-1β (Messerli et al., 2010). Leukocyte activation in PET has been evidenced by 
increased plasma level of leukocyte activation markers (L-selectin, elastase) as well as 
increased number of various leukocyte-derived microvesicles and upregulation of NF-ќB 
(Lok et al., 2009). STBM activate neutrophils, as evident by exposure of CD11b and 
formation of neutrophil extracellular traps (NETs), present in large numbers in intervillous 
spaces of preeclamptic placentas (Gupta et al., 2005, Gupta et al., 2006). In contrast, 
release of cytokines and gene expression by human endothelial cells remained 
unaffected by PE plasma microvesicles (Donker et al., 2005). Nevertheless, in co-culture 
with monocytes, increased expression of ICAM-1 could be observed suggesting a 
complex interaction between microvesicles including STBM, monocytes to which they 
are mostly bound, and endothelial cells contributing to the proinflammatory state of PE 
(van der Post et al., 2011).  
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Complement inhibition 
It could be speculated that complement regulatory proteins such as CD46 (membrane 
cofactor protein), CD55 (decay accelerating factor) and CD59 (membrane inhibitor of 
reactive lysis) are expressed on STBM since trophoblasts express high levels of these 
immunosuppressive proteins (Hsi et al., 1991, Holmes et al., 1992). These proteins are 
known to contribute towards prevention of complement-mediated lysis and protection of 
the extra embryonic tissues from maternal anti-paternal cytotoxic antibodies. Thus one 
could speculate that adverse pregnancy outcomes associated with immune-
dysregulation could involve reduced expression and altered function of these 
complement regulatory proteins. Complement activation constitutes an integral part of 
increased systemic inflammatory response of PE. Increased C-reactive protein exposing 
microvesicles have been reported in PE compared to normal controls (Biro et al., 2007). 
The physiologic role of this protein is to bind to phosphotidylcholine on surface of dead 
or dying cells or bacteria to activate the complement system via C1Q complex. Thus, C-
reactive protein exposing microvesicles could contribute to the proinflammatory state of 
PE. 
Angiogenesis 
STBM as well as platelet-derived microvesicles in PE, expose transmembrane vascular 
endothelial growth factor (VEGF) receptor Flt-1 (Lok et al,.2008) It is possible that Flt-1 





Tolerance and Immunoregulation 
The modulation of immune response is among the most important functions of 
microvesicles in pregnancy and is crucial in maintenance of tolerance.  Failure to 
modulate maternal immune response can lead to placentation failure which in turn may 
lead to partial or total rejection of the fetus. Circulating placental microvesicles at term 
express more FasL and are more efficient in suppression of genes involved in T cell 
apoptosis, compared to those derived from women at preterm labour (Taylor et al., 
2006). T cell signaling components such as CD3-zeta, JAK3 and STAT5 are suppressed 
by placental microvesicles isolated from maternal blood in normal pregnancies 
(Sabapatha et al., 2006). It is proposed that the inability to suppress such signaling 
molecules results in a failure to impair maternal T cells as well as NK cells sufficiently 
leading to pregnancy losses (Sabapatha et al., 2006). Human placental microvesicles 
express various NKG2D ligands, binding of which to NKG2D receptor bearing cells such 
as CD8+T cells, NK cells, etc. reduced their in vitro cytotoxicity (Hedlundet al., 2009), 
suggesting a role of STBMs in tolerance of pregnancy. Specific suppression by 
apoptosis and signaling of maternal cytotoxic T cells and NK cells may be achieved 
partially by Fas L and HLA-G expression by circulating STBM. There is evidence to 
suggest that this mechanism may be dysregulated in adverse pregnancy outcomes such 
as PET and RM. Preeclamptic women’s sera induce insufficient suppression of T cell 
signaling (TCR-CD3 zeta) and their decreased apoptosis compared to that from the 
normotensive controls, suggesting a deficiency in a serum factor in preeclampsia that 
may be involved in T cell suppression in normal healthy pregnancies (Whitecar et al., 
2001). In contrast to normal uncomplicated pregnancies, sera from women experiencing 
RM induce increased T cell proliferation, production of Th1 cytokines and decreased T 
cell apoptosis (Taylor et al., 2004). The extent to which immune-dysregulation and 
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maternal immune maladaptation to the semi-allogeneic feto-placental graft contributes to 
the pathogenesis of adverse pregnancy outcomes is still unclear and further 
investigation into the roles of placental microvesicles in disease etiology and 
pathogenesis is required.  
1.3  Generation, Isolation, and Quantification of STBM 
1.3.1 Current limitations 
Current methods of measurement of microvesicles are beset with limitations. 
Microvesicles and exosomes in ultracentrifuged pellets of biological fluids such as cell 
culture medium, plasma or urine can be demonstrated by electron microscopy. However, 
this method is not quantitative and requires extensive sample preparation. Western 
Blotting can determine the expression of known proteins in pelleted materials; however, 
vesicle numbers or sizes cannot be determined. ELISA assays cannot capture all 
vesicles and only detect soluble antigens. Conventional flow cytometry cannot detect 
microvesicles below the 300 nm in size and therefore excludes exosomes (Perez-pojol 
et al., 2007). Atomic force microscopy has been used recently for studying size 
distribution and number of CD41+ microvesicles in plasma but this method is highly 
labor-intensive (Yuana et al., 2010). Dynamic light scattering method determines the 
size by light scattered from particles under Brownian motion; however, it is biased 
towards measuring larger particles (Lawrie et al., 2009).  
1.3.2 Newer methodologies 
Recently, a new method, Nanoparticle Tracking Analysis (NTA), has been described for 
real-time visualization, determination of size, size distribution, number as well as 
phenotype (by using fluorescent antibodies) of biological vesicles in suspension. NTA  
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has distinct advantages over the conventional methods (Dragovic et al., 2011). In NTA, 
nano-sized particles in Brownian motion suspended in liquid are visualized by light 
scattering using a light microscope. A video is taken and the NTA software then 
determines the size and total concentration of particles by relating their Brownian motion 
to size. The authors evaluated NTA to analyze human placenta-derived microvesicles 
and human plasma-derived microvesicles. They demonstrated various advantages of 
using NTA; such as analysis of vesicles by NTA is rapid, and vesicles as small as 30 nm 
can be measured. Also, surface marker expression to determine their cells of origin and 
function can be done by using fluorescent antibodies. Thus, NTA extends the power of 
flow cytometry in the field of research of microvesicles and nanovesicles.  
1.4    The immune System 
The immune system defends an organism against exogenous microbial infection as well 
as responds to endogenous danger signals such as tissue necrosis, apoptosis and 
malignancy. For optimal function, the immune system must recognize a wide variety of 
pathogens, distinguish them from the self and neutralize them. Disorders of immune 
system can result in autoimmune diseases, inflammatory diseases, malignancies or 
even immunodeficiency. The vertebrate immune system can be described into two 
intimately linked arms, the innate and the adaptive immunity (Figure 1.12). 
 






1.4.1  Innate and adaptive Immunity 
The innate immune system constitutes the first line of defense against pathogens, reacts 
rapidly to danger signals, and works in a non-specific manner. The cells of innate 
immune system include phagocytes (macrophages, dendritic cells, neutrophils), 
basophils, eosinophils, mast cells and NK cells. They recognize and respond to 
pathogens in a generic way, but do not confer long lasting or protective immunity to the 
host.  
The major functions of vertebrate innate immune system include: 
a. Recruitment of immune cells to sites of infection, through production of chemical 
mediators known as cytokines 
b. Activation of complement cascade to identify bacteria, activate cells, and 
promote clearance of apoptotic debris 
c. Identification and removal of foreign substances by leukocytes 
d. Activation of adaptive immune system by the process of antigen presentation 
e. Constitution of a physical and chemical barrier against pathogens 
The adaptive or specific immune response takes longer time, about 4-7 days, to 
develop, and is activated by the innate immune system. It provides the organism with 
immunological memory or the ability to recognize and remember specific pathogens and 
lasting protection against re-encounters with it. Re-encounters with the specific antigen 
can result in stronger immune response. The adaptive immune response comprises T-
cell mediated cellular immunity and B-cell mediated, humoral or antibody immunity. 
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The major functions of adaptive immune system include: 
a. Recognition of specific non-self antigens in the presence of self, during the 
process of antigen presentation 
b. Generation of responses tailored to maximally eliminate specific pathogens 
c. Development of immunological memory whereby each pathogen is remembered 
by a signature antibody. These memory cells can be called upon quickly to 
eliminate a pathogen in case of subsequent re-encounters. 
d. Mounting stronger immune response against specific antigen in case of 
subsequent re-encounters.  
1.4.2  Cells of innate immune response 
The cells of innate immune system include phagocytes (macrophages, dendritic cells, 
and neutrophils), basophils, eosinophils, mast cells and NK cells. The phagocytic cells of 
the immune system include macrophages, dendritic cells and neutrophils that engulf or 
phagocytose pathogens or particles. Once inside the cell, the invading pathogen is 
contained inside an endosome which merges with a lysosome resulting in death and 
digestion of the particle. Phagocytes patrol the organism searching for pathogens and 
are also capable of secretion and reacting to a group of highly specialized molecular 
signals called cytokines which helps recruitment of other cells to the site of inflammation. 
Phagocytosis of host’s own cells is part of normal physiological turnover and growth of 
tissue. Following death of host cells by apoptosis or necrosis, phagocytes are 
responsible for their clearance prior to growth and development of new healthy cells and 
thus promote healing following tissue injury. 
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Macrophages 
These are large phagocytic leukocytes capable of moving out of vascular system and 
entering intercellular spaces in search of invading agents. In tissues, organ-specific 
macrophages are differentiated from phagocytic cells present in blood such as the 
monocytes. Macrophages are the most efficient phagocytes. They are capable of 
generating and releasing reactive oxygen species to destroy pathogen.  
Neutrophils 
Neutrophils along with basophils and eosinophils are granulocytes due to presence of 
toxic substance containing granules in their cytoplasm designed to destroy pathogens. 
Neutrophils are the most abundant phagocytes representing 50-60% of total circulating 
leukocytes. 
Dendritic cells (DCs)  
Debdritic cells are phagocytic cells present in tissues that are in contact with external 
environment such as skin and inner mucosal lining of respiratory system (nose, lungs), 
gastro-intestinal system and reproductive system (uterus). They are of utmost 
importance in the process of antigen presentation to T cells and serve as the most 
efficient antigen-presenting cell (APC), between the innate and adaptive immune system 
(Banchereau and Steinman, 1998).  
In their immature state, the DCs act as sentinels and through effective antigen sampling 
via macropinocytosis and endocytosis, they sense their macroenviroment for danger 
signals from pathogens and endogenous sources. On sensing a danger signal, they 
undergo maturation, mount an immune response leading to inflammation and 
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subsequent priming of adaptive immunity. The process of maturation is coupled with 
increased antigen processing and antigen presentation by upregulation of MHC I and 
MHC II components, upregulation of co-stimulatory molecules such as CD40, CD80 and 
CD86 and increased cytokine production such as IL-12, IL-6, TNF-α and IL-10.  
DCs that have undergone functional maturation migrate to the T cell region of secondary 
lymphoid organs (Randolph et al., 2005) and are highly efficient at stimulating T cells via 
3 distinct signals. These are: a) antigen specific TCR stimulation, b) costimulatory 
surface signals such as CD80/CD86 stimulation of CD28 receptor on T cells and c) 
cytokines such as IL-12. DC internalized antigens are degraded, loaded onto MHCII 
complexes and presented to CD4+ T helper cells that express antigen-specific TCR. 
Endogenous antigens are processed and loaded onto MHC I complex for priming of 
cytotoxic CD8+ T cells that express the specific TCR. 
DCs can polarize adaptive immunity by inducing specific CD4+ T helper cell subsets 
(Guermonprez et al., 2002). The three main subsets of T helper responses are Th1, Th2 
and Th17 responses. Differentiation of naïve CD4+T cells into Th1 requires IL-12p70 
production by DCs (Trinchieri, 2003). Th1 cells produce IFN-γ and TNF-β and Th1 
immunity protects against intracellular pathogens and tumors. Th2 cells produce IL-4, IL-
5 and IL-13 and are responsible for humoral immunity against parasites. Th2 polarisation 
requires IL-4 and OX40L (Ito et al., 2005).  
Th17 cells have been described more recently. They produce cytokines such as IL-17A, 
IL-17F and IL-22 and its differentiation is promoted by TGF-β, IL-6, IL-21 and IL-23 (Korn 
et al., 2009). They are implicated in defense against extracellular pathogens and 
development of autoimmune and inflammatory diseases. 
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Dysregulated immune cell activation is detrimental to systemic homeostasis and can 
lead to disorders of immunity. Regulatory T cells (Tregs) are specialized for immune 
suppression and they are important in maintenance of peripheral immunological self-
tolerance. They suppress effector T cell proliferation and thus can actively downregulate 
activation and proliferation of self-reactive T cells (Sakaguchi et al., 2008). Naturally 
occurring Tregs arise in the thymus. T cell activation usually induces a population of 
Tregs and they are CD4+CD25+Foxp3+. In addition to Tregs, DCs with tolerogenic 
properties exist that are crucial regulators of immunity (Morelli and Thomson, 2007). 
Immature DCs have been known to be tolerogenic and mature tolerogenic DCs do not 
express strong stimulatory signals. These tolerogenic DCs can present antigen to 
antigen-specific T cells but provide inadequate co-stimulatory signals or deliver net co-
inhibitory signals for effector T cell activation and proliferation. This may result in T cell 
anergy, T cell death or Treg generation or expansion. Thus tolerogenic DCs have been 
shown to suppress autoimmunity (Menges et al., 2002, Verginis et al., 2005).  
DC subsets 
In the periphery, DCs act as sentinels for pathogens or peripheral self-antigen, then 
undergo maturation and migrate via lymphatics toward draining lymphoid organs and are 
categorized as migratory DCs (Wilson et al., 2003). Lymphoid tissue resident DCs are 
immature in steady state, CD11chiCD45loMHC IIint, which can be further described into 2 
subsets: CD8+ conventional DC (cDC) and CD8- cDC (Naik, 2008). On maturation they 
become migratory and are MHChi. 
Plasmacytoid DCs (pDC) resemble plasma B cells at resting state (Liu, 2005), are 
CD11cint, express low levels of MHC I, MHC II and co-stimulatory molecules all of which 
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are upregulated upon activation. Once activated they produce high amounts of IFN-α 
and concomitantly acquire DC morphology and function. 
In the human blood, DCs are a heterogenous cell population originating from bone 
marrow precursors and they make up about 1% of circulating PBMCs (Kassianos et al., 
2010). Based on CD11c expression, lin-HLADR+ blood DC can be described in the 
CD11c-plasmacytoid (pDC) and CD11c+ myeloid DC subsets. pDCs represent about 
18% of blood DCs and express CD123, CD303 and CD304. mDCs comprise over 70% 
of blood DCs and are of 3 types: CD1c+ subset (19%), CD16+ subset (50%) and CD141+ 
subset (3%) which is the rarest and least studied 
Due to rarity of DCs, in vitro experiments have mostly relied on DCs generated from 
human blood monocytes cultured with GM-CSF and IL-4 (Sallusto and Lanzavecchia, 
1994). A disadvantage of this method is that DCs generated this way are only found in 
vivo following an inflammation (Shortman and Naik, 2007). 
1.4.3  Cells of adaptive immune response 
T cells and B cells are the major cells of adaptive immune system involved in cell-
mediated and humoral or antibody-mediated immune response respectively. T cells 
recognize a non-self target only after antigens have been processed and presented in 
combination with a self-receptor called MHC molecule. The major subtypes of T cells are 
cytotoxic T cell (CD8+) that recognize antigen coupled to MHC I molecule and helper T 
cell (CD4+) that recognize antigen coupled to MHC II molecule. In contrast, B cell 
antigen-specific receptor is an antibody molecule on B cell surface and recognizes whole 
pathogens without any need for antigen processing. 
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1.4.4  Cytokines 
Cytokines are small cell signaling protein molecules secreted by various immune cells 
used extensively in intercellular communication. Major cytokines of immune system, their 
sources and functions are summarized in Figure 1.13. 
 
Figure 1.13: Cytokines of immune system. Reproduced from Calier, 2008. 
Immunological cytokines can be described into those that enhance proinflammatory 
cellular responses, type 1 such as IL-6, IL-8,IL-12, IL-1β, and IFN-γ and type 2 (IL-2, IL-
4, IL-10, TGF-β, IL-13) which favour an anti-inflammatory humoral response. IL-8, 
secreted by APCs and epithelial cells is proinflammatory, and serves as a chemical 
signal that attracts neutrophils to the site of inflammation and promotes angiogenesis. IL-
6 acts as a pro-inflammatory cytokine, secreted by DCs, macrophages and T cells. It is 
among the most important mediators of acute phase inflammatory response and known 
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to stimulate acute phase protein synthesis, neutrophils and B cells. It is antagonistic to 
Tregs. However, it is also anti-inflammatory and this effect is mediated through its 
inhibitory effects on TNF-α and IL-1 and activation of IL-10. IL-12 is secreted by 
activated B cells, macrophages, and other antigen-presenting cells (APCs), but its 
production is inhibited by IL-4 and IL-10. Its biological activities include enhancement of 
cytotoxic T cells and lymphokine activated killer (LAK) cell generation and activation, 
increased natural killer (NK) cell cytotoxicity, induction of activated T cell and NK cell 
proliferation, induction of IFN-g production by NK cells and T cells. IFN-γ is known to 
enhance MHC class I and II expression on nucleated cells and stimulate many of the 
effector functions of mononuclear phagocytes. TNF-α, a potent endogenous pyrogen, 
secreted by activated macrophages and other cells, stimulate acute phase reaction such 
as fever, apoptosis, and sepsis. Recently described, IL-17 is a product of activated T 
lymphocytes and its biologic activities include stimulation of IL-6 and IL-8 production and 
enhanced ICAM-1 expression on human foreskin fibroblasts. 
 1.5    The Immunology Maternal-Fetal Interface in Health and 
 Disease 
The immunology of maternal-fetal interface has long been an area of intense research 
interest. Immunomodulation and establishment of tolerance at this dynamic interface are 
pivotal to successful coexistence between mother and the feto-placental semi-allograft 
expressing both maternal (self) and paternal (non-self) genes (Hunt et al., 2006, Mor et 
al., 2009, Robertson et al., 2010).  During normal healthy pregnancy cytotoxic adaptive 
immune response is diminished, regulatory adaptive immunity is enhanced (Guerin et 
al., 2009, Lebar et al., 2010), while innate immunity remains intact to continue to provide 
host defense against infection and facilitate interaction with fetal tissue for optimal 
placentation (Barrientos et al., 2009, Dekel et al., 2010, Nagamatsu et al., 2010). 
Perturbations in this complex physiology could lead to adverse outcomes such as PE or 
pregnancy losses involving partial or complete rejection of the feto-placental graft 
(Figure 1.14). 
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 Figure 1.14: Maintenance of early pregnancy. An implanted embryo (approximately 14 
days after conception) and the processes necessary for maintenance of an early 
pregnancy. Reproduced from Norwitz et al., 2001. 
Maternal-fetal interface can be described as interface 1 and 2. Interface 1 involves local 
interactions between maternal immune cells and fetal trophoblasts in the decidua 
(specialized endometrium of pregnant uterus) at the implantation site that is dominant 
during early pregnancy. Interface 2 involves interactions between circulating maternal 
  37
immune cells and the syncytiotrophoblasts that form the outermost villus surface of the 
haemochorial placenta. This surface expands with the growth of the placenta for the 
support of the growing fetus and becomes the dominant interface towards the end of 
pregnancy engaging systemic instead of local immune response (Figure 1.15)                  
 
Figure 1.15: Schematic representation of the maternal-fetal interface. When trophoblast 
invades the deciduas, the immune cells constitute 40% of total decidual cell population 
and are dominated by mediators’ innate immunity, such as decidual NK cells (70%), 
macrophages (25%) and dendritic cells (1-2%) while T cells (10%) are more sparsely 
distributed, Reproduced from Weiss et al., 2009. 
1.5.1  The defense mechanisms of placenta 
The placental trophoblasts are directly exposed to maternal blood and tissues. Uniquely, 
these fetal trophoblasts evade detection and destruction by maternal immune system 
programmed to attack non-self foreign antigen bearing cells or tissues. Fetal 
trophoblasts are derived from external trophectoderm layer of the blastocyst and choose 
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one of the three developmental pathways: a) remain quiescent as villus cytotrophoblasts 
(stem cells), b) proliferate and migrate into the deciduas as extravillus  or invasive 
cytotrophoblast cells (forming chorion membrane),  or c) they may merge into 
syncytiotrophoblast cell layer (a thin rim of multinucleated cytoplasm with no cell 
boundaries) to facilitate diffusion of gases and nutrients from mother to fetus.   
Specific protective mechanisms for the trophoblasts include strict regulation of 
expression of HLA class I antigen (primary stimulators of graft rejection) and complete 
repression of HLA class II antigen (encode paternally derived foreign HLA class II HLA 
D). The extravillus cytotrophoblasts do not express HLA class Ia antigen (HLA -A or -B) 
and instead they express HLA-C and HLA class Ib antigen (HLA E, -F or –G) which may 
confer them the ability to dampen immune response and cytotoxicity exerted by NK 
cells, T cells and macrophages (Shakhawat et al., 2010). The syncytiotrophoblasts at the 
outer most layer of the placental villi, subjected to maximum exposure to maternal cells, 
express no membrane-bound HLA class 1a antigens. However, there is evidence of 
presence of HLA class 1b antigens in syncytiotrophoblast (Chu et al., 1998). Neither 
class of trophoblasts express HLA class II antigen. 
Members of B7 family of costimulatory molecules such as B7H1 are uniquely expressed 
on syncytiotrophoblasts. This protein has lymphocyte inhibitory properties and therefore 
positioned to interfere with maternal circulatory lymphocyte activation (Petroff et al., 
2003).  Similarly, apoptosis inducing members of TNF supergene family such as TNF-α, 
FasL, TRAIL are also expressed on trophoblasts (Phillips et al., 2001) and are pivotal 
components of a successful pregnancy in order to diminish cytotoxic adaptive immunity. 
Also trophoblasts contain Indoleamine 2,3 dioxygenase (IDO), an inhibitor of tryptophan 
metabolism which is essential for T cells. It is therefore believed that IDO may contribute 
towards T cell inhibition by trophoblasts. The trophoblast expresses high levels of 
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complement regulatory proteins such as CD46, CD 55 and CD59 which are critically 
important for its protection against maternal anti-paternal cytotoxic antibodies since 
complement activation leads to opsonization and destruction of immunologic target (the 
fetal cells). Immunosuppressive molecules that permeate the pregnant uterine 
environment such as progesterone from placenta, prostaglandin E2 from resident 
macrophages and decidual stromal cells and the balance between Th1 and Th2 
cytokines driven by progesterone contribute in maintenance of the unique 
immunomodulation of uterus.  
There is evidence to show that the trophoblast secretes active FasL via exosomes and 
microvesicles (Abrahams et al., 2004, Frangsmyr et al., 2005). Thus, placenta-derived 
subcellular microvesicles containing an array of above mentioned protective proteins 
and RNA may play a significant role in immunomodulation critical for normal pregnancy. 
Their release is increased and composition is altered in pregnancy complications such 
as PE. Their role in RM remains yet unclear. Investigation into the pathophysiological 
relevance of placental microvesicles in PE and RM would be interesting and beneficial to 
the field of reproductive immunology.  
1.5.2  Role of the pregnant uterus in local immune adaptation 
Maternal immunological adjustment to accommodate the semi-allergenic feto-placental 
graft during pregnancy includes a significant change in the relative proportions of 
leukocyte subpopulations of the deciduas. The adaptive immune cells such as the T 
cells and B cells become scarce. The uterine NK cells population shifts from cytotoxic 
phenotype of peripheral NK cells (pNK) to cytokine producing benign phenotype 
decidual NK cells (dNK). Invasive trophoblasts become admixed with dNK cells, 
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macrophages and dendritic cells reflecting extensive maternal-fetal immunological cross-
talk (King at al., 1989, Bulmer et al., 1988, Gardner et al., 2003).  
Decidual NK cells have major roles in pregnancy such as facilitation of trophoblast 
invasion, decidual and placental angiogenesis and uterine vascular modifications. 
Alterations in decidual NK cell optimum number and activation status may play a role in 
RM. Decidual macrophages produce immunosuppressive factors which can limit 
inflammatory responses at maternal-fetal interface and may facilitate vascular 
remodeling in normal placentation.  
The role and phenotype of decidual dendritic cells as the most potent antigen presenting 
cells is less clear and deserve further investigation. Animal studies have shown that they 
are critical for successful implantation and remodeling of maternal vasculature.  Decidual 
DCs processing and presenting fetal antigens to the uterine T cells could be tolerogenic; 
insufficiently stimulating or inhibiting the T cells and thus contribute towards maternal 
tolerance of the fetal graft. Treg cells population reside and expand in deciduas. In 
adverse pregnancies such as PE, there are decreased numbers of peripheral and 
decidual Tregs suggesting their important role in maintenance of tolerance of pregnancy. 
1.6  Adverse Pregnancy Outcomes Associated with Immune-
Dysregulation (PE and RM) 
Maternal immune maladaptation, excessive trophoblast apoptosis, dysregulation of the 
placental vasculature (anti-angiogenesis), inflammatory and hemostatic imbalance 
leading to pathological placentation are thought to be the common pathophysiologic 
mechanisms underlying PE and RM (Alijotas et al., 2009, Li et al., 2009, Matthiesen et 
al.,2012). PE involves partial rejection of the feto-placental graft with late manifestation 
(after 20 weeks), while RM represents complete rejection earlier in gestation (prior to 20 
weeks) (Taylor et al., 2004) and these clinical outcomes are determined by time of onset 
as well as magnitude of the initial insult. Hence we were interested to study these two 
patient groups with adverse pregnancies. 
Recurrent miscarriage (RM) is a vexing problem that affects up to 5% of couples trying 
to establish a family [Roman, 1984]. Recognized risk factors for RM include genetic 
disorders, structural pathologies, thrombophilias, endocrine and autoimmune diseases 
as well as environmental factors.  
Over the last two decades, there has been increasing evidence that immunologic factors 
play an important role in RM [Gleicher, 1985; Xu, 1990; Stagnaro-Green, 1990; Maier, 
1989; Silver, 1994; Coulam, 1995] and up to 70% of RM cases are associated with 
immunologic factors. Maternal adaptation of immunological responses to the implanting 
embryo is crucial for establishment of feto-placental unit. Inappropriate humoral or 
cellular responses have been demonstrated in patients with RM [Toth, 2010; De Carolis, 
2010]. Various humoral abnormalities in RM include presence of anti-phospholipid 
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antibodies, anti-thyroid antibodies, anti-nuclear antibodies, anti-ovarian antibodies, and 
increased immunoglobulin M levels.  
Increased /inappropriate cellular immune responses in RM (Table 1.2), include 
increased number and cytoxicity of natural killer (NK) cells in maternal peripheral blood 
(Kwak-Kim et al., 1995) and endometrium (Clifford et al., 1999), raised Th1 cytokine 
levels in endometrium (Lim et al., 2000), elevated Th1/Th2 cell ratios in peripheral blood 
(Kwak-Kim et al., 2003), increased number of IL-17+ T cells, reduced numbers and 
function of Foxp3+ regulatory T cells (Treg) in peripheral blood (Lee et al., 2011)  and 
increased proportion of Th17 cells in peripheral blood and deciduas (Wang et al., 2010). 
Raised systemic and local inflammatory immune responses observed in RM may be 
induced by, among other factors, a currently emerging subject of much interest, the fetal 
cell debris including STBM.  Defective trophoblast invasion resulting in abnormal 
uteroplacental perfusion and oxidative stress in PE and RM, may result in qualitative and 
subsequent functional changes in STBM.  The role of STBM in immune-dysregulation of 
RM remains insufficiently explored and deserves further investigation. 
 
Table 1.2. Th1/Th2/Th17 and Treg cells in normal pregnancy and miscarriage. 
.Reproduced from Saito et al., 2010.  
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RM is defined as three or more consecutive miscarriages and generally, evaluation is 
performed after the third miscarriage. However, the physician may initiate work-up 
following two miscarriages, particularly in the setting of prior euploid miscarriages, 
advancing maternal age and concomitant infertility (Stephenson et al., 2007). This is why 
women with history of 2 or more consecutive miscarriages with all or some of the 
aforementioned factors were also recruited in our study. 
Several features suggest that RM is a distinct clinical entity: (1) a woman’s risk of 
miscarriage is directly related to the outcomes of previous pregnancies, (2) the observed 
incidence of RM (1%) is much higher than that expected by chance alone (0.34%), (3) 
unlike sporadic miscarriage, RM tends to occur even if the foetus is euploid, (4) RM 
seems to affect women with specific reproductive characteristics (Table 1.3). 
                        
Table 1.3. Reproductive characteristics associated with poor pregnancy prognosis and 
RM. .Reproduced from Rai et al., 2006.  
In early 2012, Beaman and colleagues introduced the term RSAI (recurrent spontaneous 
abortion of immunological origin) and defined it as the loss of two or more consecutive 
pregnancy losses with same partner prior to 20-28 weeks of gestation where endocrine, 
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anatomic, genetic and infectious causes have been ruled out (Beaman et al., 2012). This 
group of patients are the focus of our research interest in this study. 
Current and future treatment options in RM associated with immunologic factors are 
summarized in Table 1.4, which are primarily antithrombotic, anti-inflammatory and 
immunosuppressive. Immune-regulators have been proposed recently which may have 
protective effects on trophoblasts, thus facilitating appropriate trophoblast differentiation 
and invasion and finally optimal placentation. To date the treatment options in RM of 
immunologic origin remain at best, limited and empiric. None of the treatment through 
randomized control trial has proven effective yet. It has been argued that when patients 
are selected for poor prognosis, namely those with positive immune tests, elevated NK 
cells or a greater number of miscarriages, the benefit of immunotherapy could be 
significant. 
               
Table 1.4. Present and possible future treatment options in RM. Reproduced from 
Matthiesen et al., 2012.  
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1.7  Summary of Introduction 
Placental syncytiotrophoblast microvesicles (STBM) are membrane-bound, biologically 
active, subcellular vesicles shed into maternal circulation during pregnancy as normal 
turnover of the placental surface. They have emerged as novel vehicles of intercellular 
communications at maternal-fetal interface. Quantitative and possibly qualitative STBM 
changes take place in adverse pregnancy outcomes such as pre-eclampsia (PE). 
However, the role of STBM in recurrent miscarriage (RM) remains unclear. There has 
been increasing evidence in recent years that immunologic factors, both humoral and 
cellular, play an important role in RM. Raised systemic and local inflammatory immune 
responses observed in RM may be induced by the fetal cell debris including STBM.  The 
role of STBM in immune-dysregulation of RM remains insufficiently explored. 
Investigation into the pathophysiological relevance of placental microvesicles in RM 
would be interesting and beneficial to the field of reproductive immunology. In the 
context of RM, interactions between STBM and antigen presenting cells, DCs and 
macrophages have not been investigated. Knowledge regarding the effect of STBM 
stimulation of DCs and macrophages bridging innate and adaptive immunity would 
provide an insight in to the immunopathogenesis of RM. Similarly, composition and 
differential expression of STBM protein and lipid are not known to date and 
determination of these biologically active contents of STBM would be helpful to unravel 
pathways involved in pathogenesis of RM. Finally, the roles decidual DCs in health and 
disease have not been sufficiently explored yet. An elaborate investigation of phenotype 
and functions of different decidual DC subsets in RM would elucidate in vivo alterations 
of this most efficient antigen presenting cell population and contribute towards a better 
understanding of RM.
1.8 Aims of the Study 
Biologically active, placental STBM are considered novel vehicles of intercellular 
signaling in normal as well as adverse pregnancies. At the highly dynamic maternal-
foetal interface, STBM are in constant contact with maternal immune cells, including the 
DCs and macrophages bridging innate and adaptive immunity.  
The aim of this study is to explore immunogenicity of STBM in the context of RM where it 
may have pathophysiological relevance similar to PE. Women with PE were studied as a 
comparison group. Specific aims of this study are to:  
i) Investigate whether STBM stimulate DCs & macrophages more in disease 
compared to health, 
ii) Identify STBM bioactive contents, e.g. proteins and lipids, and determine 
whether they differ in disease and health, and 
iii) Understand the distribution and role of decidual DC subsets at maternal-fetal 
interface in disease and health. 
1.8.1 Investigate whether STBM stimulate DCs & macrophages more in disease 
compared to health 
STBM are known to be proinflammatory. To date, most studies from this field have 
focused on peripheral blood mononuclear cells (PBMC) or monocytes stimulation. As 
antigen presenting cells (APC) uptake, process and present the foetal antigen to T cells, 
we decided to investigate STBM (normal and pathogenic) stimulation of DCs and 
macrophages. Cytokine production and changes in surface phenotype were studied. 
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1.8.2 Identify STBM bioactive contents, e.g. proteins and lipids, and determine 
whether they differ in disease and health  
STBM are biologically active by virtue of presence of proteins, lipids, DNA and RNAs. 
However, the basis of their proinflammatory, procoagulant and anti-endothelial function 
is not known. We investigated STBM (normal and pathogenic) protein and lipid 
composition by mass spectrometric approach.  
1.8.3 Understand the distribution and role of decidual DC subsets at maternal-
fetal interface in disease and health 
Optimum maternal immune adaptation to the developing semi-allogeneic feto-placental 
graft is pivotal to normal pregnancy outcome. However, the role of decidual DCs in 
immunedysregulation in RM remains insufficiently explored. We investigated the role of 
decidual DC subsets in women with RM.  We used 13-colour flow cytometry to 
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Chapter 2: Materials and Methods 
 
2.1  Subjects and Sample Collection 
The cases were patients with PE or history of RM. RM was defined as 2 or more 
consecutive pregnancy losses prior to 20 weeks of gestation where anatomic, infectious, 
chromosomal and endocrine causes were ruled out. Preeclampsia was defined as 
increased blood pressure (≥140/90 mm Hg) that occurred after 20 wks of gestation in 
previously normotensive women, accompanied with proteinuria ≥0.3g/day. The control 
group was gestational age-matched subjects (within two gestational weeks, similar mode 
of delivery) with no apparent related pregnancy complications.  
Placental samples and peripheral blood samples were collected at the time of delivery or 
loss. Decidual tissues (decidua basalis) from central placental bed were collected 
following Caesarean delivery. All samples were processed within 2 hours. All samples 
were collected from the National University Hospital affiliated to the National University 




2.2  Cell Biology Techniques 
2.2.1   Placental microvesicle (STBM) preparation  
2.2.1.1 In vitro villous explant culture 
Placental basal plate/decidua was carefully removed to access placental villous tissue. 
Three areas/cotyledons of 50 cents coin size were randomly sampled and rinsed in ~1L 
ice cold sterile PBS until blood-less, further cut into smaller pieces weighing ~200 mg, 
rinsed in PBS again. One such piece was distributed to each 100 mm culture dishes and 
then finally cut into explants/fragments of 5 mm. Completed medium (DMEM-F12 
supplemented with 1% antimycotic/antibiotics, 10% heat-inactivated fetal bovine serum) 
was placed in hypoxic incubator to equilibrate to 8% O2 for at least 3 hrs or preferably 
overnight. After equilibration, Flasks were parafilmed to cover filtered cap and kept in 
fridge to become ice-cold prior to adding to explants.  Explants were cultured in 100 mm 
culture dishes in DMEM-F12 supplemented with 1% antimycotic/antibiotics, 10% heat-
inactivated fetal bovine serum for 72 hrs for generation of STBM at 370C in 8% oxygen in 
the hypoxic incubator (Galaxy 48R CO2 incubator with O2 control 0.1 to 19% range).  40-
50 explants in 15ml complete medium were set per culture dish and 6 culture dishes 
were set per sampling region per sample. At the end of culture, the supernatant was 
collected and frozen. The villous explant samples were snap-frozen for additional 
analysis and formalin-fixed (4% formalin in 1XPBS) for paraffin sectioning. All frozen 
samples were stored at -800C until further analysis. Fresh tissue was also preserved 




 2.2.1.2 Isolation and characterization of STBM 
STBM was isolated by differential centrifugation of explant culture supernatant (Gupta et 
al., 2005). Briefly, 30 ml culture supernatant was subjected to centrifugation at 1000 g for 
10 min (for separation of whole cells), 10,000 g for 10 min (for separation of large 
cellular organelles, such as mitochondria, golgi, ER, etc.) and finally, 100 000 g for 60 
min at 40C using Beckman polyallomer centrifuge tubes and SW 28 rotor, Beckman (for 
collecting subcellular membrane microparticles). The final pellet was collected, washed 
in 1.5 ml PBS at 7000 g for 10 min and resuspended in 0.5 ml sterile PBS and stored at -
200C until use. The protein content in each STBM preparation was quantified by 
Bradford assay (Pierce, Rockford, IL) after lysis in RIPA lysis buffer with protease 
inhibitor cocktail for 30 min on ice. Typical STBM preparations yielded 0.2-0.4 mg/ml 
vesicles. STBM size distribution and concentration was determined by Nanoparticle 
Tracking Analysis (NTA) method (Dragovic et al., 2011). STBM samples were subjected 
to further evaluation by flow cytometry using trophoblast-specific marker placental 
alkaline phosphatase (Abcam, Cambridge, UK), apoptosis marker Annexin V (Invitrogen, 
Camarillo, CA), quantitative real-time PCR for detection of fetal gene SRY and finally 
scanning electron microscopy (SEM), described in details under sections 2.3 and 2.4. 
2.2.2   Cell culture 
2.2.2.1 Isolation of monocytes from human buffy coats 
Peripheral blood leukocytes from healthy donors, in the form of buffy coat, were obtained 
from the National University Hospital Blood Donation Centre, Singapore with Institutional 
ethics approval. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-
Paque (GE Healthcare, Uppsala, Sweden) density gradient centrifugation. The cells 
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were plated for 2 hr at 370C followed by removal of non-adherent cells, mainly 
lymphocytes. The adherent fraction, mainly monocytes, was harvested. Monocytes 
isolated by this method were >90% pure, based on the expression of CD14 as judged by 
flow cytometry. 
2.2.2.2 In vitro culture of monocyte-derived DC and macrophages 
The isolated monocytes were cultured at a density of 1.5 x 106/ml in RPMI containing 
10% (v/v) bovine calf serum (BCS), 100 units/ml penicillin, 100 µg/ml streptomycin, 2 
mM L-glutamine and 1mM sodium pyruvate and 0.0012% (v/v) β-mercaptoethanol. The 
cells were cultured for 6 days in the presence of 20 ng/ml of GM-CSF (R & D Systems 
Inc, Minneapolis, MN) and 40 ng/ml of IL-4 (R & D Systems Inc) to differentiate the cells 
to DCs. Differentiation of monocytes to macrophages was performed by adding 20 ng/ml 
of M-CSF (R & D Systems Inc). 
2.2.2.3 DC and macrophage stimulation  
Differentiated cells were harvested. Cell stimulations were performed in triplicates at a 
density of 0.7X106 cells/ml. For flow cytometry, 1X106 cells/ml were seeded per 
stimulation. 100 µg/ml of STBM were used to stimulate cells for 24 hrs at 370C in 5% 
CO2. LPS/IFN-γ stimulation was used as positive control, while unstimulated cells, as 
negative control.  At the end of incubation period, cultured supernatants were collected 
and frozen at -200C until assayed.  
2.2.2.4 Total, naïve and memory CD4+ T cell isolation 
Non-adherent PBMCs following monocyte adhesion, were either processed fresh for T 
cell isolation, or stored at 40C overnight in RPMI supplemented with 20% BCS for T cell 
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isolation the next day (CD4+ T cell isolation kit II, naïve CD4+ T cell isolation kit and 
memory CD4+ T cell isolation kit, Miltenyi Biotec, Germany), following manufacturer’s 
instructions.  
2.2.2.5 Mixed Leukocyte Reaction (MLR) 
For MLR, 0.1 ml T cells (2x106/ml) were co-cultured for 7 days with 0.1 ml DCs or 
macrophages (2x105/ml) in activation medium, in the presence or absence of STBM. 
The culture supernatant was collected and IFN-γ, IL-10 and IL-17 were measured by 
ELISA.   
 
 
2.3 Molecular Biology Techniques 
2.3.1 DNA extraction and qrt-PCR of STBM 
350 µl STBM suspension (0.2-0.4 µg/µl) were used for automated DNA extraction by 
EZ1 Bio Robot (Qiagen) using the DNA Blood protocol, EZ1 DNA Blood Mini Kit reagent 
cartridges with elution volume 50 µl. Real-time PCR reactions were performed in 
triplicates for each sample in total reaction volume of 25 µl with the following 
components: TaqMan PCR Master Mix (Applied Biosystems)-12.5 µl, forward & reverse 
primer- human beta globin gene HBB (100 µM each)-0.06 µl, forward & reverse primer- 
human male gene SRY (100 µM each)-0.11 µl, TaqMan probe (50 µM) FAM – 0.05 or 
0.11 µl, DNA template- 5 µl, nuclease-free water- to 25 µl final reaction volume. The 
reaction mixtures were run on the ABI Systems 7000 Real-Time PCR machine using the 
absolute quantitation method. The reaction conditions were as follows: carryover 
decontamination via uracil-N-glycosylase (UNG) for 2 min at 500C, AmpliTaq Gold pre-
activation for 10 min at 950C, 35 cycles of melting step for 15 sec at 950C and combined 
annealing and extension step for 1 min at 600C. Corresponding calibration 
curve/standard curve for house keeping gene and target gene were run in parallel with 
each analysis. Absolute concentrations of the target gene DNA were expressed as 
copies/mg of STBM. 
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 2.4  Imaging, Protein and Lipid Chemistry Techniques 
2.4.1  Nanoparticle Tracking Analysis (NTA) 
NanoSight LM10 system (NanoSight Ltd., Amesbury, UK) was used for real-time 
visualization of STBM and determination of their size distribution as well as 
concentration as previously described (Dragovic 2011). Briefly, 300 µl of diluted STBM 
suspension in double filtered PBS (1:200) was loaded onto the sample chamber and a 
video of 30 seconds duration was recorded, with a frame rate of 30 frame per second. 
Brownian movement of each particle was tracked and measured. In NTA method, the 
velocity of particle movement is used to calculate particle size. Particle movement as 
captured in the video was then analysed by NTA software to give a distribution of vesicle 
size and concentration at each vesicle size.    
2.4.2 Immunofluorescence labeling and flow cytometry of STBM 
Annexin V (AxV)-PI Assay- 500 ul STBM suspension isolated from 30 ml culture SN was 
washed in PBS (X2), resuspended in 1XAxV binding buffer (0.2-0.4 µg/µl), and aliquoted 
100ul per tube. 5ul AxV and 10ul PI buffer were added in, followed by incubation at room 
temperature for 15 min in the dark. 400ul AxV binding buffer was finally added, and 
subjected to flow cytometry within an hour. 10 000 events were read.  
 Placental Alkaline Phosphatase (PLAP) Assay- 500 ul STBM (0.2-0.4 µg/µl), was 
washed in PBS (X2), resuspended in 1XPBS, aliquoted 100ul per tube. Labeling was 
performed with primary antibody (PLAP Mo anti-human) 100ul, 1:100 dilution (10ug/ml), 
incubated at 370C, for 30 min in the dark. 200ul PBS was added. STBMs were washed 
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at 13000 rpm for 10 min, followed by incubation with secondary antibody (Alexa-Fluor 
488 FITC Conj Goat Anti-Mo), 100 ul, 1:100 dilution for 30 min at 40C. STBM were then 
washed in PBS, resuspended in 250-500ul PBS and finally subjected to flow cytometry 
within an hour. 10 000 events were read. 
2.4.3 H/E & immunohistochemical staining of placental syncytiotrophoblast layer 
4% buffered formalin-fixed placental villi were embedded in paraffin and 5 µm thick 
sections were prepared. After deparaffinization with xylene, rehydration with decreasing 
concentrations of alcohol and fixation with additive methanol, slides were stained in 
eosin for 1.5 minutes and in thiazine or hematoxylin for 30 seconds. 
Slides were destained with increasing concentrations of alcohol and then subjected to 
antigen retrieval by boiling in Sodium Citrate Buffer (10mM Sodium Citrate, 0.05% 
Tween 20, pH 6.0) for 2.5 minutes using a pressure cooker. Immunohistochemical 
staining was initiated by permeabilization first, in case of intracellular antigens, using 
methanol-acetone or CHAPS. For surface antigens of syncytiotrophoblast, eg., PLAP, 
blocking step was initiated first, followed by primary and secondary antibody incubation 
steps. Slides were washed in between steps 3X, for 5 min with PBST, finally air-dried in 
the dark, stained with DAPI, covered with cover slip and finally sealed with nail varnish.  
2.4.4 Western blotting of STBM 
STBM proteins (40 µg) resolved by 1D SDS-PAGE were electroblotted to nitrocellulose 
membrane (Hybond-C Extra, Amersham Biosciences) and blocked for an hr in 5%BSA 
in TBST before an overnight incubation at 40C in primary antibody (rabbit anti-human 
PLAP or FasL and beta-actin, Abcam). Primary and secondary incubations were done in 
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blocking buffer. The membrane was washed 3X for 10 mins with TBST and finally 
visualized using SuperSignal® West Pico Chemiluminescent Substrate (Pierce). 
2.4.5 Scanning electron microscopy of STBM 
For SEM examination, 40 µg STBM was diluted in 1 ml PBS. Primary fixation was done 
by 2.5% Glutaraldehyde in 1xPBS overnight followed by distilled water wash at RT for 
10-20 min, X3-5. Secondary fixation was performed with 1.4% Osmium tetroxide in 
distilled water at RT for 1-2 hrs followed by washing. Dehydration with increasing 
concentration of alcohol was then instituted with incubation at RT for 10 min at each 
concentration (25%, 50%, 70-75%, 90-95%, and 100% ethanol). Dehydration with 100% 
ethanol was performed twice. Finally, the specimens were subjected to critical point 
drying, mounted on specimen stub by silver or graphite paste, coated with gold and 
analyzed by Phillips JSM 5600LV scanning electron microscope. 
2.4.6 ELISA of stimulation assay supernatant 
ELISA on supernatant of DC/macrophage stimulation assay was performed using 
commercially available human cytokine detection kits. The Duoset® ELISA Development 
System (R & D Systems Inc, Minneapolis, MN) was used for TNF-α and IL-17, while the 
BD OptEIATM ELISA set (BD Biosciences, San Dieago, CA) was obtained to quantitate 
IL-6, IL-8, IL-10, IL-12p40, IL-12p70 and IFN-γ and the Ready-SET-Go! Kit (eBioscience, 
San Dieago, CA) was used for IL-23 detection.  
2.4.7 Flow cytometry of stimulated DCs 
Following stimulation by STBM, DCs were harvested and incubated for 30 minutes on 
ice with fluorochrome-conjugated antibodies, e.g., CD80, CD83 (BD Biosciences), CCR7 
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(R & D), CD86, MHC I, MHC II (Ancell, Bayport, MN), isotypes IgG1 (Ancell). For non-
conjugated antibodies, e.g., CD40 (eBioscience), a second step of incubation was 
performed using a PE-conjugated goat-anti-mouse IgG. Data acquisition and analysis 
were performed on a Dako Cyan flow cytometer using the Summit 4.3 software (Dako-
cytomation).  
2.4.8 Confocal microscopy of stimulated DCs 
DCs were cultured on Lab-Tek Chambered Coverglass (Nunc) with STBM stimulation or 
left untreated for 24 hrs and then stained with PE-conjugated CD11c antibody. To detect 
STBM internalized by DC, non-conjugated FasL antibody (Abcam) and secondary 
antibody (FITC-conjugated goat-anti mouse antibody) were used. Confocal images were 
taken using the FLUVIEW FV 1000 Confocal Microscope System, version 1.6.2.5 and 
images were analysed using the Zeiss Image Browser 4.0. Various antibodies used in 
this study are shown in Table 2.1 and 2.2. 
 Table 2.1 
Antibodies used in this study to characterize STBM
Antibody Host Species Dilution Specificity Source
Placental Alkaline Phosphatase (PLAP) Mouse 1:100 Human Abcam







Antibodies used in this study to characterize DCs
Antibody Conjugate Specificity Dilution Source
CD40 Unconjugated Human (Costimulatory molecule expressed by APCs) 1:100 eBioscience
CD80 PE Human (Costimulatory molecule expressed by APCs) 1:20 BD
CD83 PE Human (Costimulatory molecule expressed by APCs) 1:20 BD
CD86 PE Human (Costimulatory molecule expressed by APCs) 1:100 Ancell
CCR7 PE Human (Marker for cell migration) 1:25 R & D
MHC I FITC Human (Marker for antigen presentation) 1:100 Ancell
MHC II FITC Human (Marker for antigen presentation) 1:100 Ancell
IgG1 Isotype PE PE 1:100 Ancell
IgG1 Isotype FITC FITC 1:100 Ancell
Goat anti-mouse PE mix for CD40 PE 1:50
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2.4.9  Protein separation, in-gel digestion and LC-MS/MS analysis of STBM 
 proteins 
STBM protein lysate from ~200µl STBM suspension was subjected to acetone 
precipitation overnight, reduced with 10mM dithiothreitol (DTT) and alkylated with 20mM 
iodoacetamide (IAA). Proteins (~50µg) were separated on a 10.5-14% Tris-HCL SDS-
gel (BIO-RAD) and stained with PageBlueTM protein staining solution (Fermentas) 
containing Coomassie Brilliant Blue G-250 dye. Each lane in gel was divided into 13 
slices and in-gel digestion was carried out with trypsin. Samples were lyophilized and 
reconstituted with 10 µl of 0.1% formic acid.  
For LC-MS/MS analysis, each digestion product was separated by a 60 minute gradient 
elution at a flow rate 0.30µl/min with Agilent 1200 HPLC system interfaced with 6520 
QTOF MS system. The analytical column was Zorbax 300SB (75µm ID, 150 mm length) 
packed with C-18 resin (300 A, particle size 5µm). Mobile phase A consisted of 100% 
H2O with 0.1% formic Acid, and mobile phase B consisted of 100% acetonitrile with 0.1% 
formic acid. The mass spectrometer was operated in scanning mode and recorded a 
range of 120 m/z to 2200 m/z. Ions were selected based on charge state and then by 
abundance.  
The data were searched against human IPI database using Mascot program (Matrix 
Science) and validated using X! Tandem in Scaffold program (Proteome Software). The 
following search parameters were used in all of the Mascot searches: maximum of 3 
missed trypsin cleavages, maximum error tolerance 300 ppm for MS and 0.8 Da for 
MS/MS. Proteins were designated as hits only when there were at least 2 unique 
peptides matches and Protein Identification Probability value >95%. 
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The quantitation of protein expressions by spectral counts for each identified proteins 
(defined as total spectral counts for all the peptides of a given protein) was carried out 
using Scaffold program (Proteome Software). Only proteins with spectral counts ≥10 and 
a ratio of spectral counts between two groups (patients and normal controls) of > 2 or < 
0.5 were tested further by t-test and validation. We performed t-test to examine 
significant difference in protein spectral counts between STBM proteins from patients 
and normal controls, p value of <0.05 was used to determine differentially expressed 
proteins which would then be candidates for validation by immunohistochemistry and/or 
western blotting.  
2.4.10 Immunohistochemistry of villous explants for LC-MS data validation 
Villous explants were fixed and paraffin-embedded. Tissue microarrays were prepared. 
IHC was performed according to manufacturer’s instructions (Leica Microsystems). 
Briefly, after deparaffinization and heat-induced epitope retrieval, endogenous 
peroxidase blocking was performed. Slides were incubated with primary antibodies for 
45 minutes. Antibodies used are listed in Table 2.3.  After washing, the sections were 
exposed to anti-rabbit poly-HRP-IgG in 10% animal serum for 10 minutes, followed by 
DAB reagents for 3 minutes. DAB reaction was stopped and counterstaining with 
hematoxylin was performed for 5 minutes. After washing, sections were dehydrated and 
finally mounted in synthetic mounting media (Electron Microscopy Services, Hatfield, 
USA). Controls included omission of primary antibodies. After IHC, tissue microarray 
slides were scanned, analyzed and scored (Leica Microsystems slide scanner and 






 Table 2.3 
Antibodies used for Immunohistochemistry
Antibody Source Cat# Host Conditions
S100-A11 Abcam ab97329 Rabbit 1:5000   pH9
Histone H2A Abcam ab18255 Rabbit 1:2500   pH6
Histone H4 Abcam ab10158 Rabbit 1:10000   pH6
Fibronectin Abcam ab2413 Rabbit 1:250   pH6
Integrin Beta 3 Abcam ab75872 Rabbit 1:100   pH6
Annexin IV Abcam ab33009 Rabbit 1:250   pH9
Peroxiredoxin 6 Abcam ab59543 Rabbit 1:2000   pH9
Annexin A1 Abcam ab33061 Rabbit 1:100   pH9
Clathrin Heavy Chain Abcam ab21679 Rabbit 1:5000   pH6
 
 
2.4.11 Lipid extraction from STBM 
Lipids were extracted using the modified Bligh and Dyer’s method (Bligh and Dyer 
1959). Briefly, 750µl of ice cold chloroform: methanol (1:2, v/v) was added to 
microparticles resuspended in 100 ul of PBS. The mixture was vortexed vigorously for 1 
minute. After shaking at 1200rpm at 4oC for 1 hour, 250 µl ice cold chloroform and 350 µl 
of ice cold water was added to the samples. The samples were then subjected to 
another 1 min vortexing. The phases were separated by centrifugation at 9000 rpm and 
the lower organic phase containing the lipids was transferred to a fresh tube. Lipids were 
re-extracted from the remaining aqueous phase with 500 µl of ice cold chloroform. The 
two extracts were pooled and vacuum-dried. Dried lipid film was then reconstituted in 
chloroform: methanol 1:1 (v/v) prior to analysis by mass spectrometry. The lipid samples 
were spiked with a mixture of internal standards prior to mass spectrometry. The 
standard cocktail contained -PA 17:0/17:0, PE 17/17:0, PG 14:0/14:0, d31-PI 18:1/16:0, 
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PS 14:0/14:0, PC 14:0/14:0, C17 ceramide, C8 glucosylceramide, d6-cholesterol, d6-
cholesterol ester and SM 18:1/12:0. 
 
2.4.12  ESI-LC MS MRM of STBM lipids 
Quantification of individual lipid molecular species was performed using an Agilent 1200 
HPLC system coupled with an Applied Biosystem Triple Quadrupole/Ion Trap mass 
spectrometer 3200Qtrap  (Applied Biosystems, Foster City, CA) as described previously 
(Shui et al., 2011, PMID:21573191). In multiple reaction monitoring (MRM) based 
experiments, the first quadrupole, Q1, is set to pass the precursor lipid ion of interest to 
the collision cell, Q2, where it undergoes collision induced dissociation. The third 
quadruple, Q3, was set to pass the structure-specific product ion characteristic of the 
precursor lipid of interest. Lipids were infused using an Agilent 1200 system and 
separated on Silica based column chromatography (Luna 3u Silica 100A, 150 X 2mm, 
Phenomenex, USA) before being introduced into the mass spectrometer. The separation 
was carried out using a gradient as described previously (Shui et al., 2011, PMID: 
21573191). The mobile phase A had chloroform: methanol: 28% NH4OH (895:100:5) 
and B had Chloroform : methanol : water : 28% NH4OH (550:390:55:5). Mass 
spectrometry was recorded under both positive and negative modes, respectively. Under 
the negative mode, phosphatidylglycerol (PG), PI, phosphatidylserine (PS), phosphatidic 
acid (PA), phosphatidylethanolamine (PE) and ganglioside (GM3) were eluted and 
separated by a step gradient elution, lasting a total of 48 min per sample. Under the 
positive mode, phosphatidylcholine (PC), ceramide, glucoceramide and sphingomyelin 
(SM) were separated by another 50-min step gradient elution. The flow rate was 
maintained at 0.3ml/min throughout the run with the injection load of 10μl for both 
negative and positive mode. Free cholesterol (chol) and its congeners, e.g. cholesteryl 
esters (CE), 24-hydroxycholesterol (24-OHC), 7β-hydroxycholesterol (7-OHC), 7-
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ketocholesterols (7-KC), and squalene  were analyzed using HPLC/APCI/MS/MS as 
previously described (Shui et al., 2011, PMID:21621788). 
2.4.13 Flow Cytometry of decidual DCs 
Pieces of decidual tissue were rinsed, chopped finely, and digested overnight with 0.8 
mg/ml collagenase (Type IV, Worthington-Biochemical) in RPMI (PAA) with 10% FCS 
(AutogenBioclear) for 2 hr. Viability was >90% by DAPI exclusion (Sigma). RBC lysis 
was performed followed by staining for flow cytometry. Peripheral blood mononuclear 
cells were isolated by density centrifugation (Ficoll-Paque; GE Healthcare). 
Flow cytometry was performed on a BDLSRII and FACSCanto and data analyzed with 
FlowJo (Treestar). Antibodies used are listed in Table 2.4. 
Decidua samples were analyzed using the same flow strategy to map known blood DC 
subsets to peripheral tissue populations as previously described, Figure 1 (Haniffa et al., 
2012). Cells were first gated by FSC-A and SSC-A and dead cells were excluded by 
DAPI staining. Leukocytes were identified using CD45 followed by exclusion of doublets 
using the SSC-A and SSC-W. Antigen Presenting Cells (APC) were identified within the 
HLA-DR+ and Lineage- (CD3, CD19, CD20 and CD56 all in FITC) fraction. Having the 
Lineage cocktail in the FITC channel also allowed us to exclude autofluorescent 













Antibodies used for Flow Cytometry of DC Subsets in human blood & decidua
Antibody Fluorochrome Source Cat#
CD45 V500 Invitrogen HI30
CD3  FITC BioLegend SK7; UCHT1
CD7 FITC eBioscience 4H9
CD19 FITC BioLegend HIB-19
CD20 FITC BioLegend 2H7
CD56 FITC BioLegend MEM188
HLA-DR Qdot605 Invitrogen Tu36
CD14 ECD Beckman Coulter RM052
CD16 APC-H7 BioLegend 3G8
CD123 PerCPCy5.5 BioLegend 7G3; 6H6
CD11c V450 BioLegend B-ly6
CD1c PECy7 BioLegend L161
CD141 PE or APC Miltenyi Biotec AD5-14H12






2.5  Experimental Repeats and Statistical Analysis 
Results presented are representative of at least two independent experiments. Data 
were expressed as mean values of experimental triplicates ± SEM. Cytokine data had a 
non-normal distribution while the mass spectrometry data were normally distributed 
(D'Agostino & Pearson omnibus normality test). Analysis of statistical significance of 
differences in cytokine production by DCs in response to STBM stimulation were sought 
using Mann Whitney U test, while differences in STBM protein spectral counts, STBM 
protein staining intensities, STBM lipid molar fractions and frequency of DC subsets 
between patient group and normal healthy pregnant group were sought using Student’s 
two-tailed unpaired t-test. Analyses were performed using GraphPad Prism 5 software. 
Results were considered to be statistically significant if P<0.05.  
 
2.6  Buffers 
1x PBS pH 7.4 (diluted from 10x stock from Invitrogen, Singapore) 
• KH2PO4 1.76 mM 
• Na2HPO4 10.4 mM 
• NaCl 137 mM 
• KCl 2.7mM 
FACSwash buffer 
• 1xPBS 
• Heat-inactivated bovine calf serum 2.5% (v/v) (Invitrogen, Singapore) 
• Sodium azide 0.05% (w/v) 
MACS buffer 
• 1xPBS 
• 0.5% bovine serum albumin (BioRad, Singapore) 
• 2 mM EDTA 
Tris buffered saline 
• Tris-HCl, pH 7.5, 50 mM 
• NaCl 150 mM 
10 x SDS-PAGE electrophoresis buffer 
• Tris base 250 mM 
• Glycine 2.5 M 
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• SDS 1% (w/v) 
5 x reducing laemmli buffer (BioRad, Singapore) 
• Tris-HCl, pH 6.8, 250 mM 
• Glycerol 50% (v/v) 
• SDS 10% (w/v) 
• Bromophenol Blue 0.05% (w/v) 
• Dithiothreitol (DTT) 0.5 M (added fresh before use) 
10 x Western blot transfer buffer 
• Tris base 250 mM 
• Glycine 1.92 M 
• To prepare 1 x western blot transfer buffer- 10 x buffer diluted1 part to 2 parts 100% 
methanol & 7 parts deionized water 
PBS-T or TBS-T buffer 
• 1 x PBS or 1 x TBS with Tween-20, 0.05% (v/v) 
Western blot blocking and antibody incubation buffer 
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Chapter 3: Immunomodulation by Placental STBM in 
Adverse Pregnancy Outcomes 
 
3.1  Introduction 
 
Placental syncytiotrophoblast microvesicles (STBM) are shed into the maternal 
circulation during pregnancy as normal turnover of the placental surface. STBM are 
membrane vesicle populations (0.1 to 1 µm), produced as a result of syncytiotrophoblast 
apoptosis (Huppertz et al., 2006, Redman et al., 2008, Pantham et al., 2011). STBM 
also include placenta-derived exosomes (10-100 nm), secreted from endosomal 
multivesicular bodies (MVB) upon fusion with the plasma membrane (Redman et al., 
2007, Dragovic et al., 2011). Membrane vesicles are composed of lipid bilayer with 
transmembrane proteins and enclose part of cytosol of the parent cell. They are 
metabolically active by virtue of the presence of lipids, proteins and nucleic acids (Gupta 
et al., 2008, Cocucci et al., 2009, Redman et al., 2012, Rajakumar et al., 2012). They 
have the ability to directly activate T cells or transfer antigens to dendritic cells for 
subsequent presentation to T cells and can be inhibitory by induction of T cell death, 
inhibition of dendritic cell maturation or inhibition of T cell cytotoxic activity (Thery et al., 
2009). STBM may be novel vehicles for intercellular communication, especially with 
maternal immune cells at maternal-fetal interface (Southcombe et al., 2011). 
STBM are known to be proinflammatory (Germain et al., 2007, Messerli et al., 2010, 
Southcombe et al., 2011), procoagulant (Gardiner et al., 2011) immune-regulatory 
(Arkwright et al., 1994) and anti-angiogenic (Smarason et al., 1993, Gupta et al., 2005). 
They circulate in significantly increased amounts in adverse pregnancy outcomes such 
as preeclampsia (PE), which is characterized by exaggerated systemic inflammatory 
response, coagulation and endothelial dysfunction (Lok et al., 2008, Redman et al., 
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2009, Van Der Post et al., 2011). Thus, circulating STBM may play a role in the 
pathogenesis of PE and possibly other pregnancy complications such as RM, which 
involves pathological placentation. In the present study, RM was defined as 2 or more 
consecutive pregnancy losses prior to 20 weeks of gestation where infectious, 
chromosomal and hormonal causes were ruled out.  
Up to 70% of RM is associated with immunologic factors as evidenced by increased 
inflammatory immune responses in RM including increased number and cytoxicity of 
natural killer (NK) cells in peripheral blood of non-pregnant and pregnant women with 
history of RM regardless of outcome of the index pregnancy, i.e. live births or non-live 
births (Kwak-Kim et al., 1995) and endometrium (Clifford et al., 1999), raised Th1 
cytokine levels in endometrium regardless of outcome of subsequent pregnancy (Lim et 
al., 2000), elevated Th1/Th2 cell ratios in peripheral blood in non-pregnant women with 
RM (Kwak-Kim et al., 2003), increased number of IL-17+ T cells , reduced numbers and 
function of Foxp3+ regulatory T cells (Treg) in peripheral blood in non-pregnant women 
with RM (Lee et al., 2011)  and increased proportion of Th17 cells in peripheral blood 
and deciduas of RM patients with ongoing loss (Wang et al., 2010).  
 
As the role of STBM in immune-dysregulation of RM remains yet unclear, we sought to 
determine if STBM from women with history of RM, regardless of outcome of index 
pregnancy, were more immuno-stimulatory compared to normal pregnant women by 
using explant STBM to evaluate the in vitro responses of antigen presenting cells such 
as monocyte-derived dendritic cells (DC), macrophages as well as T cells.  
 
 3.2  Subject Characteristics 
We studied 22 pregnant women with RM, 13 pregnant women with PE, and gestational 
age-matched healthy normal pregnant women (Table 3.1 and Table 3.2). Of the RM 
cases, 6 had definite autoimmune disease such as systemic lupus erythematosus (SLE) 
and/or antiphospholipid syndrome (APS) that fulfilled American College of 
Rheumatology classification criteria (Tan et al., 1982, Hochberg et al., 1997, Wilson et 
al., 1999), 10 had positive antinuclear antibody or antithyroid antibody, 14 had elevated 
NK cells (>12%) and 10 had more than one poor prognostic factor. All RM patients 
received either passive immunotherapy in the form of IVIG and/or antithrombotic therapy 
(aspirin and/or heparin), while those with PE received conventional anti-hypertensive 
therapy. 
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 Table 3.1 
Maternal and foetal outcomes of STBM immunomodulation study- RM 
Normal Pregnant Controls Normal Pregnant Controls 
Live birth (n=20) Non-live birth (n=2) Live birth(n=20) Non-live birth (n=4)
Maternal age (y) 36.22[5.19] 35 [1.41] 35.27 [5.27] 33.17 [3.46]
Gestational age (w) 34.81 [7.70] 14 [5.66] 36.83 [2.61] 16 [4.54]
Number of miscarriages 2.68 [1.05] 3.5 [0.71] - -
Positive Immune Test 10 0 - -
Definite Autoimmune Disease 6 0 - -
NK cells >12% 14 0 - -
IVIG 12 0 - -
LMWH 11 1 - -
Results are mean [SD] 





Maternal and foetal outcomes of STBM immunomodulation study- PE 
Normal Pregnant Controls Normal Pregnant Controls 
Live birth (n=11) Non-live birth (n=2) Live birth (n=13) Non-live birth (n=4)
Maternal age (y) 37.17[3.82]a 33.33 [3.06] 35.17[5.38] 33.17 [3.46]
Gestational age (w) 31.82[3.24]* 16.97 [6.51] 35.35[3.09] 16 [4.54]
SBP (mm Hg) 161.50[18.95]*** 120.67[15.31] -
DBP (mm Hg) 107[6.06]*** 73[6.08]
Proteinuria (g/24h) 1.14[0.57] -
Infant birth wt (g) 1687.95[888.96]* 2650[642.25]
Placental wt (g) 395.50[121.93]** 578.75[101.21]





3.3  STBM Characterization 
Results of STBM characterization are presented in Figure 3.1. H/E and 
immunofluorescent staining of placental villous explants confirmed the integrity of the 
syncytiotrophoblast layer, shed as STBM. Scanning electron microscopy demonstrated 
expected morphology. Conventional flow cytometry and nanoparticle tracking analysis 
method showed lowest forward and variable side scatters, placental syncytiotrophoblast 
specific protein PLAP expression and STBM size distribution to be around 250 nm. 
Quantitative Real time (TaqMan) PCR analysis of STBM DNA showed amplification of 






Figure 3.1: Representative images of STBM basic characterization. A. H/E staining of 
villous explants showing deep blue syncytiotrophoblast (STB) layer at periphery (X20); 
B. Immunofluorescence (IF) image of villous explants demonstrating the bright green 
layer of STB stained for Placental Alkaline Phosphatase, PLAP (X40); C. Morphology of 
STBM by scanning electron microscopy (X10.000); D. PLAP expression of STBM by 
flow cytometry; E. Quantitative Real time (TaqMan) PCR analysis of STBM DNA for 
detection of male fetal DNA (SRY gene). 100 µl of STBM preparation was used for 
extraction of DNA by EZ1 DNA Blood Mini Kit, elution 50 µl, 3 µl/reaction used as 
template for PCR; F. Nanoparticle tracking analysis of STBM, showing STBM size to be 




3.4  Human Monocyte-Derived DCs Internalize STBM and STBM 
Do not Affect the Viability of DCs 
 
Immunofluorescent staining and confocal microscopy confirmed uptake of STBM by 
DCs, while DCs that were not exposed to STBM did not show fluorescence signal 
(Figure 3.2). STBM stimulation showed insignificant impact on DC viability based on the 




Figure 3.2: Representative confocal images of dendritic cells after being incubated with 
(top panel) or without (bottom panel) 100 µg/ml STBM for 24 hr. Monocyte-derived 
dendritic cells showing, (A) brightfield image; (B) CD11c (red); (C) STBM (green); (D) 
overlay; (E) single monocyte-derived dendritic cell with 3-D image; DC left unstimulated 
showing (F) brightfield image; (G) CD11c (red); (H) no green fluorescence in green filter. 







Figure 3.3. Representative forward scatter/side scatter (FSC/SSC) dot plots of DC, left 
unstimulated or incubated with indicated preparation of 100 µg/ml STBM or 500 ng/ml 
LPS for 24 hr.  
 80
3.5  STBM Induce Marginal Expression of Maturation Markers 
on DCs 
DCs are known to express basal levels of co-stimulatory molecules and relatively higher 
levels of MHC molecules. However, no differential expression profile of these markers 




Figure 3.4. Surface phenotype of unstimulated (immature) and LPS-stimulated (mature) 
DC (n=3). DCs differentiated from monocytes after 6 days of culture were considered 
immature DC. Harvested cells were left unstimulated or stimulated with LPS (500 ng/ml) 
for 24 hrs to allow maturation. CD40, CD80, CD83, CD86, MHC I, MHC II and CCR7 
antibodies were used to stain the DC. Filled histograms are signals obtained with isotype 




Figure 3.5. Surface phenotype of DC stimulated by STBM from woman with RM and 
gestational age matched normal control (n=2). DCs were stimulated with STBM for 24 
hrs. Filled histograms are signals obtained with isotype IgG. Open histograms are 





Figure 3.6. Surface phenotype of DCs stimulated by STBM from woman with PE and 
gestational age matched normal control (n=2). DCs were stimulated with STBM for 24 
hrs. Filled histograms are signals obtained with isotype IgG. Open histograms are 
staining with specific antibodies, red histograms, PE STBM; blue histograms, normal 
control STBM
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3.6  STBM Induce Dose-Dependent Production of Pro-
Inflammatory Cytokines Following Uptake by DCs 
 
STBM stimulated dose-dependent release of pro-inflammatory cytokines IL-8, IL-6 and 
anti-inflammatory cytokine IL-10 from DCs (Figure 3.7). Importantly, additional 48 hr 
culture of aliquots of explant culture supernatants prior to STBM isolation showed no 
evidence of bacterial growth and endotoxin contamination (data not shown).  
 
 
Figure 3.7: Normal STBM-mediated dose-dependent secretion of cytokines by 
monocyte-derived dendritic cells (n=2). Cells were left untreated (negative control) or co-
incubated for 24 h with different doses of STBM. Data is representative of at least 2 
independent experiments.
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3.7  STBM from RM Patients with non-live birth or Severe PE 
Requiring Termination are Immuno-stimulatory 
 
STBM from the RM patient with non-live birth or severe PE patients requiring pregnancy 
termination were immuno-stimulatory. This was demonstrated by significantly increased 
or a trend to increased production of pro-inflammatory cytokines in PE and RM group, 
respectively, such as IL-8 (P=0.0574 in PE), IL-6 (P<0.01 in PE), and TNF-α (P<0.01 in 
PE) by the stimulated DCs, (Figures 3.8 and 3.9, Tables 3.4 and 3.6). Placental 
histopathology was supportive, as evident by massive perivillous fibrin deposition, 
inflammation, thrombosis in RM and severe villous ischaemia in severe PE. Cytokines 
showing marginal changes in the initial stage of the study, namely IL-10, IL-12p70, IL-23, 
and IL-17, were not included in further analysis. STBM stimulated macrophages showed 




Figure 3.8. RM (non-live birth)- a trend to increased proinflammatory cytokine release by 
DCs. DCs (7 X 104 per well) were stimulated for 24 hr with placental STBM from patient 
& gestational age matched normal healthy control (n=2), LPS (positive control) or left 
unstimulated (negative control). Cytokine production was determined by ELISA. All 
experiments were performed in triplicates with at least 2 independent experiments 
carried with the same batch of samples, Results are expressed as mean values of 







Figure 3.9. Severe pre-eclampsia requiring termination- significant proinflammatory 
cytokine release by DCs. DCs were stimulated with placental STBM from patient & 
gestational age matched normal healthy control (n=2), LPS (positive control) or left 
unstimulated (negative control). Results are expressed as mean values of experimental 
triplicates ±SEM.  Histopathology of placenta shows marked villous ischaemia, villi are 






 3.8  STBM from RM or PE Patients with live birth have 
increased immunogenicity 
 
STBM from RM patients with live birth had significantly increased immunogenicity. This 
was demonstrated by production of significantly greater levels of pro-inflammatory 
cytokines, e.g. IL-6 and TNF-α (P<0.05) (Table 3.3). PE patients showed similar results 
(Table 3.5). Placental villous histology showed scattered fibrin deposition in intervillus 






Figure 3.10. RM (live birth) – significantly increased proinflammatory cytokine release by 
Dendritic cells. DCs were stimulated with placental STBM from patients & gestational 
age matched normal healthy controls (n=20), LPS (positive control) or left unstimulated 
(negative control). Results are expressed as mean values of experimental triplicates 
±SEM. Section show placental tissue with focal congestion, prominent is tissue knobs 
and scattered intervillus fibrin deposition. No infarct is noted. No fibrin thrombi identified. 








Figure 3.11. PE (live birth) – significantly increased proinflammatory cytokine release by 
Dendritic cells. DCs were stimulated with placental STBM from patients & gestational 
age matched normal healthy controls (n=11), LPS (positive control) or left unstimulated 
(negative control). Results are expressed as mean values of experimental triplicates 












Mean (pg/ml) SEM N Mean (pg/ml) SEM N P value
IL-6 529.70 181.80 20 173.20 21.52 20 0.0133
IL-8 23000 5043 20 11670 1354 20 0.1636
IL-12p40 199.50 53.84 20 120.50 11.50 20 0.2393
TNF-α 250.40 130.80 20 73.44 6.61 20 0.0066
IFN-γ 468.90 208.00 6 421.10 123.70 5 0.8559






Cytokine profile of STBM-stimulated DC (RM non-live birth) 
 
RM Normal
Mean (pg/ml) SEM N Mean (pg/ml) SEM N P value
IL-6 176.00 48.37 2 110.30 17.97 4 0.5333
IL-8 13670 954 2 15210 6247 4 1
IL-12p40 151.60 32.89 2 53.03 10.71 4 0.1333









Mean (pg/ml) SEM N Mean  (pg/ml) SEM N P value
IL-6 326.40 102.10 11 137.10 10.71 13 0.0321
IL-8 15240.00 5832.00 11 11120.00 1694.00 13 0.3247
IL-12p40 561.80 139.70 11 450.90 110.20 13 0.643
TNF-α 92.95 7.71 11 86.95 8.87 13 0.3848
IFN-γ 1115.00 137.90 6 951.40 216.90 4 0.5196





Cytokine profile of STBM-stimulated DC (PE non-live birth) 
 
PE Normal
Mean (pg/ml) SEM N Mean (pg/ml) SEM N P value
IL-6 1727.00 329.00 2 254.20 114.10 4 0.0051
IL-8 55320 22840 2 12560 5420 4 0.0574
IL-12p40 336.20 297.80 2 60.72 16.65 4 0.2089
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 Chapter 4: Proteomic Analysis of Placental 
Syncytiotrophoblast Microvesicles in Adverse 
Pregnancy outcomes 
 
4.1  Introduction 
 
Proteomes of microvesicles derived from platelets, plasma, malignant lymphocytes, 
endothelial cells, dendritic cells, mast cells, and intestinal epithelial cells have been 
published (Garcia et al., 2005, Jin et al., 2005, Miguet et al, 2006, Wubblots et al. 2003, 
Thery et al., 1999, Thery et al., 2001, Van Niel et al., 2001). Broadly, microvesicle 
proteins are either ubiquitous or specific to cells of origin. Ubiquitous proteins are most 
likely involved in microvesicle biogenesis. Examples include tetraspannins (CD9, CD63, 
CD81 and CD82), heat shock proteins (HSP70, HSP90), cytoskeletal proteins (tubulin, 
actin, actin binding proteins), metabolic enzymes, membrane transport and fusion 
proteins (annexins and RAB proteins), signal transduction proteins (protein kinases, 14-
3-3, G proteins), integrins and MHC class I and II molecules (Thery et al., 2002). 
Examples of cell-specific proteins include MHC class II in exosomes from all cells 
expressing MHC class II, CD 86 from DC-derived exosomes (a co-stimulatory molecule 
for T cells), T-cell receptors for T-cell derived exosomes, and immunoglobulin family 
members (CD54 on B cells, P-selectin on platelets). In contrast to exosomes, 
microvesicles released by apoptotic cells do contain nuclear and organeller proteins, 
DNA, messenger and microRNA. Both exosomes and microvesicles may provide 
unconventional routes of protein secretion (Nickel et al., 2005).  
Multiple pathophysiologic factors are implicated in PE including maternal immune 
maladaptation to the feto-placental unit, excessive fetal trophoblast apoptosis, and 
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increased trophoblast debris shedding.  These result in increased systemic inflammatory 
response, haemostatic activation, endothelial dysfunction, and metabolic changes 
(Roberts, 2002). Primary reduction in placental perfusion leading to tissue hypoxia and 
oxidative stress may result in qualitative and subsequent functional changes in STBM. 
Serdar et al. showed quantitative changes in serum, placental and decidual lipid and 
protein oxidation products and anti-oxidant concentrations to be significantly associated 
with preeclampsia (Serdar et al., 2003). Proteomic analyses of normal and preeclampsia 
placentas (Gharesi-Fard et al., 2010), syncytiotrophoblasts (Okamura et al., 1981), 
cytotrophoblasts (Hoang et al., 2001, Hu et al., 2007, Hong et al., 2008, Johnstone et al., 
2011) and plasmas (Blumenstein et al., 2009, Rasanen et al., 2010, Liu et al., 2011) 
have been previously reported. While the role of STBM in PE is a vibrant area of 
research, the role of STBM in RM remains unclear.   
We hypothesized that STBM proteins are differentially expressed in PE and RM 
compared to normal pregnancies. Our objectives were to determine protein and peptide 
components of STBM that can incite pathogenic responses in pregnancy complications 
and explore whether these STBM protein expressions differ in pathologic and normal 
pregnancies. As opposed to earlier studies which employed 2D-LC-MS/MS (Rasanen et 
al., 2010, Johnstone et al., 2011), 2D PAGE and MALDI TOF/TOF (Gharesi et al., 2010, 
Shin et al., 2011), and 2D DIGE (Blumenstein et al., 2009), we used 1D Gel-LC-MS/MS 
approach to improve sensitivity. 
 4.2  Subject Characteristics 
In a series of three ESI LC-MS/MS experiments, we studied 3 pregnant women 
complicated with preeclampsia, 2 pregnant women with recurrent miscarriages, and 2 
healthy normal pregnant women. The clinical characteristics of the women and maternal 
and neonatal outcomes are summarized in Table 4.1. The patients underwent 




Maternal and foetal outcomes of STBM proteomics study 
 
PE (n=3) RM (n=2) Normal  controls (n=2)
Maternal age (y) 31[2.16]a 30[5.66] 37.6[4.88]
Gestational age (w) 36.09[0.95] 36.35[2.93] 35.86[3.03]
SBP (mm Hg) 173.25[31]*** 103.5 [19.09] 116.25[15.31]
DBP (mm Hg) 109.5[13.2]*** 67[9.9]] 76.5[5.58]
Proteinuria (g/24h) 1.14[0.57] - -
Infant birth wt (g) 2658[792.02] 2845[827.31] 2302.5[38.89]
Placental wt (g) 508.33[79.74] 760[84.85] 500[70.71]
aResults are mean [SD], comparisons using two-sample t test (patient group, ie, PE or RM, versus  
 normal pregnant controls), P<0.05 *, P<0.0001 ***   
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 4.3  Identification of STBM proteins by 1D Gel-LC-MS/MS 
Three gels from PE group and 2 gels from RM group including gestational age-matched 
healthy controls were analyzed and representative gels are presented in Figures 4.1 (a) 
and 4.1 (b). When lanes of STBM protein extracts from pathologic pregnancies are 
compared to that from normal healthy pregnancies, staining intensities show definite 
differences in several gel bands shown in Figure 4.1. After in-gel digestion, the tryptic 
peptides of each gel slice were analysed by LC-MS/MS. Over 300 STBM proteins were 
identified based on previously mentioned criteria in section 2.4. Spectral counts were 
used to quantify expression level of proteins in the whole lane. 
 
Figure 4.1: Representative 1-D SDS PAGE gel images of protein extracts from STBM.  
(a) Lane 1: molecular weight marker. Lanes 2, 3 & 4: Normal STBM. Lanes 5, 6 & 7: PE 
STBM. Loading volume: 20 uL per lane (~50 ug of proteins).  
(b) Representative 1-D SDS PAGE gel images of protein extracts from STBM. Lane 1: 
molecular weight marker. Lanes 2 & 3: RM STBM. Lanes 4 & 5: Normal STBMs. 




4.4  Global Overview 
The STBM proteins were subjected to GO (gene ontology) analysis to identify major 
biological processes, cellular components and molecular functions. The major cellular 
components include membrane, cytoskeleton, cytoplasm as well as nucleus suggesting 
these microvesicles population indeed resulted from apoptotic membrane blebbing 
(Figure 4.2). The major molecular functions of STBM proteins include binding (proteins, 
nucleotides, receptors, transcription factors), enzyme regulation, transcriptional 
regulation, and molecular transduction (Figure 4.3). Finally, the major biological 
processes associated with STBM proteins include biological regulation, metabolic 
processes, immune response, apoptosis, adhesion and localization (Figure 4.4). 
 























 4.5  Identification of Differentially Expressed STBM Proteins in 
Adverse Pregnancies and Healthy Controls 
We identified over 14 STBM proteins differentially expressed between pathologic and 
normal pregnancies, listed in Tables 4.2 and 4.3, notable among them are annexins, 
histones, integrins, fibrinogens, fibronectin, peroxiredoxins, clathrin and protein S-100 
A11. All of these, except histones, were upregulated in adverse pregnancies. Their 











 Table 4.3 






Functional association of proteins differently expressed in STBM from patients 






4.6  Validation of Proteomics Results by Immuno-
histochemistry (IHC) analysis 
IHC analysis of placenta for validation of LC-MS/MS-based STBM-proteomics data 
confirmed presence of all the selected proteins in the syncytiotrophoblast layer at 
periphery, which is shed as STBM, shown in Figure 4.5, 4.6, and 4.7. Negative controls 
showed no signals, Figure 4.8. There was a trend towards downregulation of all proteins, 
namely, histones, annexins, integrins, peroxiredoxins, fibronectin, protein S100, and 
clathrin (Figure 4.9) and Tables 4.5 and 4.6. 
 
Figure 4.5: Representative images of Immunohistochemical validation of mass 
spectrometry-based STBM proteiomic data in placental villous tissues. There was a 
trend towards decrease in the studied protein expressions in PE and RM placental villi. 




Figure 4.6: Representative images of Immunohistochemical validation of mass 
spectrometry-based STBM proteiomic data in placental villous tissues. There was a 
trend towards decrease in the studied protein expressions in PE and RM placental villi. 




Figure 4.7: Representative images of Immunohistochemical validation of mass 
spectrometry-based STBM proteiomic data in placental villous tissues. There was a 
trend towards decrease in the studied protein expressions in preeclampsia (PE) and 
recurrent miscarriages (RM) placental villi. Proteins are localized in the trophoblasts. 




Figure 4.8: Representative images of negative controls of placentas of PE and RM 




Figure 4.9: Summary of Immunohistochemistry analysis of placenta of PE and RM 
patients (a) PE-STBM protein expressions; (b) RM-STBM protein expressions.
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Table 4.5 
Immunohistochemical validation of RM STBM protein expression -- based on 
staining intensity  
 
RM Normal
Mean SEM N Mean SEM N P value
Annexin A1 2266.69 243.34 13 3091 193.901 8 0.0406
Annexin IV 2680.15 317.35 13 3406.25 255.125 8 0.1259
Clathrin HC 4368.23 206.903 13 4859.25 242.786 8 0.1481
Fibronectin 883.615 161.633 13 1337.63 187.724 8 0.0893
Histone H2A 1592.85 132.047 13 2091.63 203.172 8 0.0440
Histone H4 3059.31 144.681 13 3369.63 221.248 8 0.2344
Integrin B3 962.077 224.9 13 1465.88 463.424 8 0.2872
Perioredoxin 543.385 130.234 13 609.25 60.348 8 0.7093
S100A11 1185.69 148.802 13 1512.13 139.868 8 0.1541





Immunohistochemical validation of PE STBM protein expression -- based on 
staining intensity  
 
PE Normal
Mean SEM N Mean SEM N P value
Annexin A1 2777.17 267.953 12 3091 193.901 8 0.4026
Annexin IV 3034.25 234.685 12 3406.25 255.125 8 0.3091
Clathrin HC 4258.17 360.172 12 4859.25 242.786 8 0.2322
Fibronectin 1590.58 234.659 12 1337.63 187.724 8 0.4493
Histone H2A 1850.25 249.996 12 2091.63 203.172 8 0.4988
Histone H4 2882.25 162.992 12 3369.63 221.248 8 0.0866
Integrin B3 1199.08 235.909 12 1465.88 463.424 8 0.5801
Perioredoxin 790 115.85 12 609.25 60.348 8 0.1121
S100A11 1611.67 184.414 12 1512.13 139.868 8 0.4903














Chapter 5: Lipidomic Analysis of Placental 
Syncytiotrophoblast Microvesicles in Adverse 
Pregnancy outcomes 
5.1  Introduction 
Defective trophoblast invasion resulting in abnormal uteroplacental perfusion and 
oxidative stress in pre-eclampsia and RM may result in qualitative and subsequent 
functional changes in STBM. Besides bioenergetics, lipids are also known to play 
important roles in cellular signaling, membrane structure and function. Recent evidence 
shows that alterations in the lipidome mediates physiologic cellular adaptation during 
health and pathologic alterations during disease (Gross et al., 2011). 
 Pre-eclamptic plasma analysis of lipid peroxides, antioxidants, triglycerides, and 
cholesterol profiles have been previously reported (Bayhan et al., 2000, Barden et al., 
2001, Adiga et al., 2007, Lima et al., 2011, Ahmedi et al, 2012, Gohil et al, 2012). 
Oxidative stress and dyslipidemia in the form of increased malondialdehyde (marker of 
lipid peroxidation), decreased total anti-oxidant capacity, decreased high-density 
lipoprotein cholesterol concentration and increased total cholesterol, low-density 
lipoprotein cholesterol, very low -density lipoprotein cholesterol and  triglycerides 
concentration have been shown to be significantly evident in pre-eclampsia. In a recent 
report, Oliveira et al characterized the plasma lipid profiles of plasma samples from 
women with pre-eclampsia using a MALDI-MS approach (Oliveira et al., 2012). The main 
classes identified were glycerophosphocholines, glycerophosphoserines, 
glycerophosphoglycerols, glycosyldiradylglycerols, and glycerophosphates.  
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Weerheim et al., first reported the phospholipid composition of total microvesicles 
isolated from plasma of healthy individuals using one-dimensional high-performance 
thin-layer chromatography (HPTLC). Microvesicles contained PC (59%), SM (20.6%), 
and PE (9.4%), with relatively minor (<5%) quantities of other phospholipids (Weerheim 
et al., 2002). Subsequently, lipid composition of human B cell-derived microvesicles 
applying MALDI-MS was reported and found to be enriched in cholesterol, SM, and GM3 
(Wubblots et al., 2003). Oxidized microvesicles and apoptotic blebs stimulated 
endothelial cells to specifically bind monocytes, with oxidized phospholipids being the 
active principle responsible for their biological activity (Huber et al., 2002). Serdar and 
coworkers found changes not only in serum, but also in placental and decidual lipid and 
protein oxidation products and anti-oxidant concentrations to be significantly associated 
with PE (Serdar et al., 2003). STBM from PE placentas differ in quality with regard to 
lipid (fatty acid) composition from those from normal placentas (Cester et al., 1994). 
Reduction in lipid levels in STBM reduced their potential to inhibit human umbilical vein 
endothelial cells (HUVEC) proliferation and blocked their potential to induce apoptosis 
(Gupta et al., 2008). Collectively these data suggest that STBM lipid content may play a 
role in the endothelial dysfunction and immune-deregulation of PE.  
The role of STBM lipid profiles in RM patients has not been explored yet. Furthermore, 
other than sterol lipids, knowledge on polar lipids, e.g. sphingolipids and 
glycerophospholipids is lacking. These major membrane lipids form precursors for 
second messengers during cellular signalling (Fernandis et al., 2007) 
Our research interest is to study STBM lipid composition in preeclampsia and RM. Our 
objectives are to determine lipid components of STBM using lipidomics approaches and 
explore whether STBM lipid metabolites differ between normal pregnancies and 
pregnancies associated with preeclampsia and RM. Changes in various polar lipids 
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(Figure 5.1, Table 5.1) in STBM would provide an insight into the pathogenic changes 
that occur at the maternal-foetal interface during adverse pregnancies and which lipid 
components could possibly incite such changes.  
 Table 5.1 
Functional association of major polar lipid classes 
j p
Lipid class Functional Association
Phosphatidylinositol (PI) Regulatory signaling molecules involved in migration, proliferation, senescence, apoptosis
Phosphatidic Acid (PA)
Sphingomyelin (SM), Ganglioside (GM3), Ceramide (Cer) Inflammation, immune response, oxidative stress, apoptosis 
Lyso phosphatidylcholine ( Lyso PC) 
Phosphoglyceride (PG)
Phosphatidylserine (PS) Regulatory signaling molecules involved in apoptosis & coagulation
Phosphatidylcholine (PC) Binding sites for inter & intracellular proteins 
Phosphatidylethanolamine (PE)
Oxidised Phospholipids Hypoxia, redox cell signaling, activation of signaling pathways
Cholesterol (Chol) Membrane structure maintenance, regulation of signal transduction   
Cholesteryl esters (CE) Form lipid-soluble core of lipoprotein, associated with atherosclerosis
7-ketocholesterol (7-KC) Apoptosis, oxidation, inflammation




5.2  Subject Characteristics 
We investigated lipid profiles of microvesicles from 6 pregnant women complicated with 
preeclampsia, 6 gestational age-matched healthy normal pregnant women as 
preeclampsia controls, 9 pregnant women with history of RM, and 9 gestational age-
matched healthy normal pregnant women as RM controls. The clinical characteristics of 
the women and maternal and neonatal outcomes are summarized in Table 5.2. The 
patients underwent Caesarean or vaginal delivery at gestational age >28 weeks with live 
births. All RM patients received either passive immunotherapy in the form of intravenous 
immunoglobulin (IVIG) and/or antithrombotic therapy (aspirin and/or heparin), while 




Maternal and foetal outcomes of STBM lipidomics study  
PE (n=6) PE-Normal  controls (n=6) RM (n=9) RM-Normal  controls (n=9)
Maternal age (y) 37.17[3.82]a 35.17[5.38] 32.67[3.94] 36.22[5.19]
Gestational age (w) 31.82[3.24]* 35.35[3.09] 36.9[1.72] 36.36[2.88]
SBP (mm Hg) 161.50[18.95]*** 120.67[15.31] 103.5 [19.09] 116.25[15.31]
DBP (mm Hg) 107[6.06]*** 73[6.08] 67[9.9] 76.5[5.58]
Proteinuria (g/24h) 1.14[0.57] - - -
Infant birth wt (g) 1687.95[888.96]* 2650[642.25] 2823.25[533.62] 2725.56[571.65]
Placental wt (g) 395.50[121.93]** 578.75[101.21] 589.75[203.75] 565.86[73.54]
aResults are mean [SD], comparisons using unpaired t test (patient group, ie, PE or RM, versus  




5.3  Identification of STBM Lipids by ESI-LC MS MRM 
We used LC gradient elution to separate various classes of lipids (Figure 5.1) in STBM. 
The various MRM transitions for corresponding lipid species were monitored, their 
intensities measured and compared to spiked internal standards. Each lipid species in 
each sample was then normalized to the total lipid levels in the corresponding sample. 
Analyses of total lipid fraction of individual classes of lipids are shown in Figure 5.2 and 
5.3 and 5.4. Surprisingly, contrary to the normal lipid composition observed in human 
cells or plasma, SM was the most abundant phospholipid species in STBM (normal and 
pathologic) instead of PC, followed by cholesterol, PS, PC, PI, and PA. PS was 
significantly higher in the STBM from preeclampsia patients compared to that from 
normal controls (p<0.005), while SM, Cer, and LPC, showed a similar but non-significant 
trend. PI (p<0.0005), PA (p<0.005), and GM3 (p<0.05) were significantly lower in the 
STBM from preeclampsia patients relative to that from normal controls, while PC, PE, 
PG, LPI and GluCer showed a similar but non-significant trend, Figure 5.5 (a). STBM 
from RM patients showed similar trends in total levels of these lipid classes with PI 
(p<0.005), significantly lower than that from normal subjects, Figure 5.5 (b). When 
women who had 3 or more losses (n=4) were separately analyzed, the increase in PS 
compared to the control group (p<0.05), were  found to be more marked as opposed to 
the women who had 2 losses (non-significant increase). While RM patients treated with 
heparin (n=4) showed no significant STBM lipid changes relative to the control group, 
RM patients with no heparin treatment showed significantly increased PS (p<0.005) and 
significantly decreased PI (p<0.005).  
 
Among the sterol lipids, cholesterol and CE showed a trend to increase while 24-OHC 
and 7-OHC, a trend to decrease in adverse pregnancies. 
The levels of individual lipid species in STBM were quantified and are illustrated in 





Figure 5.1: Examples of polar lipid species and explanation of the lipid nomenclature. (A) 
Structure of phospholipid, where x is the headgroup. X’= choline (PC), ethanolamine (PE), 
serine (PS), inositol (PI), glycerol (PG), phosphate (PA). Each of the phospholipid species has 
two fatty acyl chains. These may vary in length and degree of unsaturation. ESI MRM lipid 
profiling is able to identify each lipid species by their headgroup (X’), total carbon number in the 
two fatty acid chains, and degree of unsaturation. In this case, there are fatty acids 18:0 and 
20:4. If X’= choline, the molecule would be PC38:4. The same nomenclature applies to both (B) 
and (C). (B) Structure of sphingolipid. X’’= hydrogen (Cer), p-choline (SM), aNeu5Ac(2-




Figure 5.2: Lipid composition of RM STBM. Comparison of mean molar fractions of 







Figure 5.3: Lipid composition of active RM STBM. Comparison of mean molar fractions of 
phospholipids and sphingolipids classes in STBM from RM patient with ongoing loss (n=1) and 









Figure 5.4: Lipid composition of pre-eclampsia STBM. Comparison of mean molar fractions of 
phospholipids and sphingolipids classes in STBM from pre-eclampsia patients (n=6) and normal 
pregnant women (n=6). 
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 Figures 5.5 (a) & (b). (a). Major Lipid Classes in PE STBM. Comparison of total fractions of 
phospholipid, sphingolipid and sterol lipid classes in STBM from preeclampsia patients (n=6) 
and normal pregnant women (n=6). * p <0.05, ** p <0.005, *** p <0.0005. Figure (b). Major Lipid 
Classes in RM STBM. Comparison of total molar fractions of phospholipid, sphingolipid, and 
sterol lipid classes in STBM from RM patients (n=9),  and normal pregnant women (n=9). * p 












 Figure 5.6: Major lipid species within each class in pre-eclampsia STBM. Comparison of mean 
molar fractions of individual phospholipids and sphingolipids species in STBM from pre-


















Figure 5.7: Major lipid species within each class in RM STBM. Comparison of mean molar 
fractions of individual phospholipids and sphingolipids species in STBM from RM patients (n=9) 
and normal pregnant women (n=9). * p <0.05
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Chapter 6 Dendritic Cells Subset Analysis in Human 
Decidua Shows Presence of CD141hi DCs 
 
6.1 Introduction 
Immunomodulation and establishment of tolerance at the dynamic maternal-foetal 
interface are pivotal to successful coexistence between mother and the feto-placental 
semi-allograft expressing both maternal (self) and paternal (non-self) genes (Hunt et al., 
2006, Mor et al., 2010, Mor et al., 2011).  During normal healthy pregnancy cytotoxic 
adaptive immune response is diminished, regulatory adaptive immunity is enhanced 
(Guerin et al., 2009), while innate immunity remains intact to continue to provide host 
defense against infection and facilitate interaction with foetal tissue for optimal 
placentation (Barrientos et al., 2009, Dekel et al., 2010, Nagamatsu et al., 2010). 
lmmune privilege at maternal-foetal interface occurs  when maternal immune cells 
encounter immunomodulatory molecules, e.g. progesterone, IDO, HLA-G and FasL from 
foetal trophoblasts, and GM-CSF from uterine epithelial cells. Perturbations in this 
complex physiology could lead to adverse outcomes such as recurrent miscarriages 
(RM) involving rejection of the feto-placental graft.  
A significant portion of unexplained RM is associated with immunologic factors as 
evident by increased inflammatory immune responses in RM including increased 
number and cytoxicity of natural killer (NK) cells in maternal peripheral blood (Kwak-Kim 
et al., 1995) and endometrium (Clifford et al., 1999), raised Th1 cytokine levels in 
endometrium (Lim et al., 2000), elevated Th1/Th2 cell ratios in peripheral blood (Kwak-
Kim et al., 2003), increased number of IL-17+ T cells , reduced numbers and function of 
Foxp3+ regulatory T cells (Treg) in peripheral blood (Lee et al., 2011),  and increased 
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proportion of Th17 cells in peripheral blood and deciduas (Wang et al., 2010). 
Collectively this evidence suggests that enhanced pro-inflammatory immune responses 
with suppressed immune regulation may be an important immune mechanism involved 
in RM. 
During pregnancy, invasive foetal trophoblasts become admixed with decidual immune 
cells including dendritic cells (DCs) reflecting extensive maternal-foetal immunological 
cross-talk (Bulmer et al., 1988a, Bulmer et al., 1988b, Gardner et al., 2003). Gardner 
and colleagues first identified and described the phenotype and distribution of human 
decidual DCs, as an HLA-DR+, CD11c+ lin- (CD3-, CD19-, CD56-, CD14-) population 
using three-color flow cytometry. The cell isolates were prepared from first-trimester 
decidual tissue. The decidual DCs comprised approximately 1.7% of CD45+ cells in the 
isolates and had the phenotype of immature myeloid DCs. Decidual DCs are critical for 
activating the T cell response mediating maternal immune tolerance of the semi-
allogeneic foetus.  
Human DC subsets in peripheral tissues, e.g. skin, lung and liver, have recently been 
reported, Figure 6.1 (A-F) (Haniffa et al., 2012). The functions of different DC subsets 
have been summarized in Table 6.1. Of the major DC subsets, CD141hi DCs is found to 
be the most efficient antigen presenting cells. DC subsets in decidual tissue from women 
with normal pregnancy or RM have not been reported yet. 
As the role of decidual DCs in immune-dysregulation of RM remains unclear, we sought 
to determine if known DC subsets, CD141hi DCs in particular, were present in decidua 
and also whether RM patients had a differential distribution of DC subsets compared to 
normal healthy pregnant women, applying 13-colour flow cytometry approach. 
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Figure 6.1 (A-D): Identification of CD141hi DCs in Human Tissues. Flow cytometry of 
peripheral blood, collagenase-treated whole skin, liver, and mechanically dispersed lung. 
Gating strategy used to identify three myeloid DC subsets within LinHLA-DR+ fraction 
(yellow gate) in tissues: (1) CD14+ DCs (blue gate), (2) CD14CD11c+ DCs (green gate), 
and (3) CD14CD11cloCD141hi DCs (red gate). Reproduced from Haniffa et al., 2012 
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Figure 6.1 (E) Frequency of CD14 DC, CD1c DC and CD141 DC in blood, liver and skin 
as a % of CD45+ mononuclear cells. Scatterplot from 6 donors are shown. *p < 0.05, 





Figure 6.1 (F): Morphology of FACS-sorted blood and skin CD141+, CD1c+, and CD14+ 
DCs and monocytes. (upper panel) visualized by GIEMSA staining of cytospin 
preparations (X100) and (lower panel) by SEM. Scale bars represent 10 mm in (upper 












6.2  Subject Characteristics 
We studied 2 pregnant women with RM and 7 gestational age-matched healthy normal 
pregnant women (Table 6.2). The patients and normal control subjects underwent 
caesarean delivery at gestational age >34 weeks. Of the RM patients, 1 had 5 previous 
unexplained RM. All RM patients received either passive immunotherapy in the form of 
IVIG and/or antithrombotic therapy (aspirin and/or heparin). 
Table 6.2 




6.3 Identification DC subsets in Human Decidual Tissues 
Using the gating strategy described in section 2.3, three myeloid DC subsets could be 
identified in human decidua: i). CD14+ DCs corresponding to blood CD14+ monocytes; 
ii)  CD11c+ DCs corresponding to blood CD11c+ DCs; and iii)  CD141hi DCs 
corresponding to CD141+ blood DCs. CD11c-CD141- cells comprised of CD123+ 
plasmacytoid DCs (pDCs) and CD34+ haematopoietic progenitor cells. Full gating 
strategy and percentage of DC populations in blood and decidual tissue from patients 
and normal controls are shown in Figures 6.2 (A-D) and 6.3. 
HLA-DR+ lineage- cells in blood and decidua comprised a CD14_ and CD14+ fraction 
(Figure 1A). Blood also contain CD16+ monocytes or equivalent cells. The CD14_ 
fraction was further separated by CD141 and CD11c expression. In blood, typical 
CD141+ DCs are a distinct population with lower CD11c expression. This population is 
mirrored in decidua as CD141hi cells with low-to-intermediate CD11c expression. 
Of the RM cases, 1 had suffered 5 unexplained miscarriages previously. This particular 
patient demonstrated a markedly higher frequency of CD141hi DCs (1.48% of CD45+ 











Figure 6.2 (A-D): Flow-cytometry gating strategy for (A) blood from RM patients, (B) 
collagenase-digested decidua from RM patients, (C) blood from normal pregnant 
controls (D) collagenase-digested decidua from normal pregnant controls. Decidua 
samples were analyzed using the same flow strategy to map known blood DC subsets to 
peripheral tissue populations (Haniffa et al., 2012). Cells were first gated by FSC-A and 
SSC-A and dead cells were excluded by DAPI staining. Leukocytes were identified using 
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CD45 followed by exclusion of doublets using the SSC-A and SSC-W. Antigen 
Presenting Cells (APC) were identified within the HLA-DR+ and Lineage- (CD3, CD19, 
CD20 and CD56 all in FITC) fraction. Having the Lineage cocktail in the FITC channel 
also allowed us to exclude autofluorescent macrophages in peripheral tissues. Three 
myeloid DC subsets can be identified in human decidua:1. CD14+ DCs corresponding to 
blood CD14+ monocytes; 2. CD11c+ DCs corresponding to blood CD11c+ DCs; and 3. 
CD141hi DCs corresponding to CD141+ blood DCs. CD11c-CD141- cells are comprised 




Figure 6.3. Frequency of DC subsets in decidua & blood as a percentage of CD45+ 
mononuclear cells. Scatterplot from 2 recurrent miscarriages (RM) patients & 7 normal 
pregnant controls (NP) (with median) are shown. Lines represent the median. Results 
are combined data from analysis of consecutive samples. 
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Chapter 7 Discussions 
 
 
7.1  Immunomodulation by Placental Syncytiotrophoblast  
 
7.1.1 Microvesicles in adverse pregnancy outcomes  
Our study investigated the effects of RM and PE associated STBM prepared in vitro from 
placental villous explants on antigen presenting cells. Explant STBM were produced 
under physiological conditions (Redman et al., 2005, Jauniaux et al., 2006, Heazell et 
al., 2008, Hung et al., 2008). Furthermore, explant STBM have been shown to be pro-
inflammatory in previous reports of monocyte or PBMC stimulation assay (Messerli et 
al., 2010, Southcombe et al., 2011). This validates the application of these shedding 
STBM as a sound and acceptable approach to study the role of placental microvesicles 
in women with adverse pregnancy outcomes.  
Microvesicles can transfer antigens to dendritic cells for subsequent presentation to T 
cells for indirect immune cell stimulation, or act independently of antigens by exposing 
immune cells to stimulatory factors, such as heat shock protein-70 or HMGB1(Thery et 
al., 2009, Redman & Sargent, 2012). Micorvesicles have been shown to affect the 
physiology of neighbouring recipient cells in various ways, from inducing intracellular 
signaling following binding to receptors to conferring new properties after the acquisition 
of new receptors, enzymes or even genetic material from the vesicles.  
 
Southcombe & co-workers have shown that STBM bind monocytes, and to a lesser 
extent B cells. STBM binding to and/or internalization by dendritic cells are likely to be 
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similar to their parent cells, i.e. monocytes. Monocytes are able to rapidly phagocytose 
STBM, up to ~60%, at the end of an hour of incubation. This suggests that the receptor 
for STBM on monocytes may be involved with phagocytosis as well as binding. Possible 
receptors include Toll-like Receptors, Receptor for Advanced Glycation End Products 
(RAGE) and Integrins. Toll-like receptors (TLR) form the major family of pattern 
recognition receptors (PRR) that are involved in innate immunity. At the maternal–fetal 
interface, TLRs are expressed not only in the immune cells but also in non-immune cells 
including trophoblasts; moreover, their expression patterns vary according to the stage 
of pregnancy. They interact with endogenous danger molecules known to be expressed 
on STBM (e.g. HSP, HMGB1, and fibronectin). Binding of TLRs results in release of 
cytokines via intracellular signaling pathway. It is known that trophoblast is able to 
‘educate’ immune cells, where constitutively expressed cytokines/chemokines, e.g. IL-8, 
MCP-1 and other signals originated from trophoblast could determine the subsequent 
immune cell behavior. This proper trophoblast–immune cell cross-talk may be essential 
for a normal pregnancy, and changes or defects in this interaction may lead to 
pregnancy complications as evidenced by animal models and clinical observations. TLR 
stimulation is known to induce fetal resorption when it occurs in early pregnancy (Li et al, 
2010). Anti-phospholipid antibodies, which is known to be involved in the pathology of 
recurrent miscarriage, pre-eclampsia and preterm labor, was also shown to induce a 
pro-inflammatory response in first-trimester trophoblast via TLR4 pathway (Mulla et al., 
2009). 
 
Furthermore, among PBMCs, STBM bind preferentially to monocytes (~80%) and B cells 
(~40%) and over a 20-hr period of incubation time, up to 90% of STBM undergo 
internalization by the monocytes. Among PBMCs, the monocytes are responsible for the 
production of the majority of the most abundantly produced pro-inflammatory cytokines 
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(TNFa, IL-6, IL-8 and IL-1b). Koppler and colleagues showed that transfer of 
microvesicles to monocytes was largely complement independent, but dependent on 
calcium and annexin V, and was found to change the cytokine profile of monocytes 
(Koppler et al., 2006).  
We found that although the STBM are pro-inflammatory to DCs and macrophages, they 
only induce a basal to modest expression of co-stimulatory molecules such as CD40, 
CD80, CD83 and CD86 as well as MHC I and MHC II molecules. Besides, they do not 
activate T cells. Our findings (Figure 3.5 and 3.6) are consistent with a recent report 
where the maternal monocytes were induced to produce pro-inflammatory cytokines by 
STBM but no upregulation of HLA-DR (MHC class II surface receptor) expression was 
observed (Southcombe et al., 2011). The authors argued that as T cells are not 
activated in normal pregnancy, a reduced expression of these markers of 
maturation/antigen presentation by APCs would reduce the potential for antigen 
presentation and prevent subsequent activation of CD4+ T helper cells. In addition, DCs 
with tolerogenic properties are known to exist, which are crucial regulators of immunity 
(Morelli and Thomson, 2007). These tolerogenic DCs can present antigen to antigen-
specific T cells but provide inadequate co-stimulatory signals or deliver net co-inhibitory 
signals for effector T cell activation and proliferation. We speculate that fetal-derived 
STBM incur similar tolerogenic properties on DCs at maternal-fetal interface. Besides, 
cytokines may be the primary signal via which STBM-mediated stimulation of DCs and T 
cells are carried out.  
Our study showed that STBM induce release of pro-inflammatory cytokines such as IL-6, 
IL-8, TNF- α and IL-12p40 from monocyte-derived DCs. These cytokines have been 
reported to be increased locally at placenta or in maternal peripheral blood in normal 
pregnancy (Montagnana et al., 2008, Kraus et al., 2010). The pro-inflammatory effects of 
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cytokines of maternal origin are considered relevant in early pregnancy-interaction with 
fetal tissues to promote embryo implantation, angiogenesis and placenta formation. 
Thus, in the process of reproduction, cytokines are actively involved in the inflammatory 
process which results in either tissue damage or repair.  
However, IL-6 is also anti-inflammatory and this effect is mediated through its inhibitory 
effects on TNF-α and IL-1 and activation of IL-10. As IL-6 has both pro-inflammatory and 
anti-inflammatory role, its presence in pregnancy may counter balance highly pro-
inflammatory cytokines. IL-12 drives Th1 differentiation of T helper cell. Bioactive IL-12 
(IL-12p70) is a p35/p40 heterodimer. IL-12p40 dimerises with IL-12p35 to produce 
bioactive IL-12. We could only observe upregulation of IL-12p40 in our study, possibly 
due to the physiologic and relatively mild nature of explant STBM stimulation that were 
used in the DC stimulation assay. STBM prepared from perfusion of placental cotyledon 
has been previously shown to upregulate IL-12p70 in PBMCs (Germain et al., 2007) and 
are also markedly more pro-inflammatory than explant STBM (Messerli et al., 2010, 
Southcombe et al., 2011).  We found significant difference in pro-inflammatory cytokine 
production in STBM-induced DCs from women with RM or PE compared to normal 
pregnancies. These findings, together with histopathological evidence of inflammation 
and thrombosis, support the notion that excessive upregulation of these pro-
inflammatory cytokines contributed to an exaggerated immune response that led to 
adverse pregnancy outcomes.  
As expected in a clinical setting, almost all of our patients received passive 
immunotherapy in the form of IVIG and/or anti-thrombotic therapy (Low molecular weight 
heparin, LMWH) /low dose aspirin, ASA).  IVIG may act possibly by correction of the 
immune dysregulation, a generally accepted phenomenon in play in immunologic RM 
(Dwyer et al., 1992; Mettheisen & Sharma, 2012). Anti-idiotypic antibodies in IVIG 
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preparations possibly bind to harmful autoantibodies associated with RM, and clear 
those. This would prevent binding of an autoantibody to its antigen, e.g. APA to 
trophoblast, prevent excessive apoptosis of trophoblast, and correct dysregulation of 
placental vasculature underlying RM. Also, anti-idiotypic antibodies may bind to and 
downregulate receptors for antigen, on APCs such as B-cell, and possibly dendritic cells 
and macrophages and modulate exaggerated immune response. Finally, it is postulated 
that anti-idiotypic antibodies may be recognized by regulatory T-cells leading to their 
activation and release of immunosuppresive lymphokines.  
 
ASA and LMWH administration in RM may have a wide array of interactions with 
immune cells, e.g.dendritic cells and macrophages. They have anti-inflammatory effects 
by blocking, (i) production of pro-inflammatory cytokines, e.g. IL-6 and TNF-α, (ii)  
antigen-antibody binding, (iii)  adhesion and chemotaxis of pro-inflammatory cells, (iv)  
and inhibiting complement activation. Besides, anti-coagulant effects; anti-apoptotic 
effects, thus conferring protection against trophoblast apoptosis; and finally pro-
angiogenic effects have also been described.  
 
The described drug effects suggest that the results of our experiments involving DC/ 
macrophage/T cell immune response using placentae from patients with history of RM 
could have been tempered by response to treatment administered to them. In our in vitro 
experiments, immune cells were derived from PBMCs from unrelated healthy donors, 
thus possible modulatory effects of drugs on immune cells were possibly excluded. 
Significant increase in level of pro-inflammatory cytokines by RM STBM could be 
demonstrated. Similar effects on trophoblasts, however, cannot be ruled out and could 
have influenced our findings, as demonstrated by mass-spectrometry analysis of STBM 
lipids. Eleven out of 20 women in RM group had received heparin (low molecular weight 
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heparin, LMWH). While RM patients treated with LMWH showed no significant STBM 
lipid changes relative to the control group, RM patients not treated with LMWH showed 
significantly increased PS (p<0.005) and significantly decreased PI (p<0.005). Of note, 
the lipid component of STBM has been shown to be associated with their pro-
inflammatory potential (Huber et al., 2002, Gupta et al., 2008). In the present study, no 
differences in DC immune responses to STBM derived from between various treatment 
groups (IVIG vs. no IVIG or LMWH vs. no LMWH) could be observed. 
 
In order to exclude these drug effects on experiments, larger number of RM patients with 
or without various treatment regimens could be studied. More importantly, study on RM 
patients in a randomized control trial on efficacy of immunotherapy needs to be 
performed to demonstrate drug effects.  
 
The placenta is known to exert immunomodulatory effects in pregnancy (Chaouat et al., 
1987) and shedding STBM which carry regulatory lipids, proteins, and microRNAs (Baig 
et al., in preparation, Tannetta et al., unpublished observations) possibly extend this 
immunomodulatory effect systemically. Specific suppression by apoptosis and inhibition 
of signaling of maternal cytotoxic T cells and NK cells may be achieved partially by FasL, 
HLA-G, and syncytiotrophoblast membrane glycoproteins expression by circulating 
STBMs (Gercel-Taylor et al., 2002, Taylor et al., 2006, Sabapatha et al., 2006, Arkwright 
et al., 1994). In another recent report, trophoblast debris generated in vitro from 
placental explants of normal placenta, were exposed to peripheral blood-derived 
macrophages (Abumaree et al., 2012). The macrophages acquired an 
immunosuppressive phenotype and functions. It was concluded that phagocytosis of 
trophoblast debris from normal placentae alters the phenotype of macrophages towards 
tolerance and away from inflammation. There is evidence to suggest that this 
 146
mechanism may be dysregulated in adverse pregnancy outcomes such as PE and RM 
(Whitecar et al., 2001, Taylor et al., 2004) and this may explain higher immunogenicity of 
pathogenic STBM.  
We found both normal and pathologic pregnancy- associated STBM to be pro-
inflammatory with a trend towards higher proinflammatory cytokine signals from DC as 
well as macrophages stimulated by pathogenic STBM. The discrepancy of these results 
may be attributed to different methodology of preparation of STBM including 8% O2 used 
in villous explant culture in our study, similar to Southcombe et al. as opposed to 20% O2 
used by the Abumaree et al., which may have effected the immunogenicity of STBM. 
Oxygen is known to influence cell turnover and expression of regulators of apoptosis 
such as p53, p21 and Mdm2 in human placental trophoblast (Heazell et al., 2008). Also, 
STBM shed by explants from normal placenta cultured in air (20% O2) has previously 
been shown be pro-inflammatory as demonstrated by up-regulation of monocyte cell 
surface expression of the adhesion molecule CD54 and production of interleukin IL-8, IL-
6 and IL-1β (Messerli et al., 2010), supporting the results of our study.     
Maternal immune dysregulation to the fetal allograft may lead to increased trophoblast 
apoptosis and dysfunction. In miscarriage, development of placento-decidual interface is 
severely impaired leading to premature, widespread onset of maternal blood flow with 
major oxidative insult by oxygen free radicals and subsequent pregnancy loss (Jauniaux 
et al., 2000). In PE the trophoblast invasion is sufficient to allow early phases of 
placentation. However, shallow trophoblast invasion results in incomplete substitution of 
maternal spiral arterial endothelium leading to impaired placentation, repetitive 
ischaemia-reperfusion phenomenon and chronic oxidative stress. This probably 
culminates into increased trophoblast shedding and raised STBM level (Knight et al., 
1998, Redman et al., 2007, Redman et al., 2008, Lok et al., 2008). Besides this 
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quantitative change, STBM possibly undergo qualitative changes due to oxidative 
damage to its content explaining their higher immunogenicity (Pantham et al., 2011). 
Investigation of STBM lipid and protein contents in pregnancy pathologies is currently in 
progress in our laboratory.  
In conclusion, we have shown STBM in health and disease (RM and PE) to be pro-
inflammatory in the context of stimulation of antigen presenting cells that bridge innate 
and adaptive immunity. Our study provides new insight into the pathophysiologic 
relevance of STBM in adverse pregnancy outcomes.   
 
7.2  Proteomic Analysis of Human Placental STBM in Adverse 
Pregnancy Outcomes  
We sought to determine the protein composition of STBM using 1D gel-LC-MS/MS 
approach to gain an insight into the pathophysiologic changes of PE and RM. To our 
knowledge this study is the first report of STBM proteome in PE and RM in comparison 
to that of normal healthy pregnancies. 
14 proteins were found to be differentially expressed between STBM derived from 
women with PE and RM compared to healthy controls; notably annexins, histones, 
integrins, fibrinogens, fibronectin, peroxiredoxins, clathrin and protein S-100 A11 which 
were upregulated with the interesting exception of histones. The annexins are calcium 
dependent-phospholipid binding proteins involved in various functions including signal 
transduction, stress response, coagulation, anti-apoptosis and lipid metabolism. Annexin 
A1 is anti-inflammatory and has been shown to be associated with inhibition of acute 
inflammation (Ahmad M Kamal, 2005). The higher expression of annexin A1(3-fold 
change, p<0.05) in PE STBM than in control STBM may suggest an attempt by 
homeostatic mechanisms to limit increased systemic inflammatory response in PE. The 
up-regulation of anti-apoptosis protein in PE STBM, such as annexin A4 (5-fold change, 
p<0.05) (Kebir et al., 2008), can be explained by increased apoptotic activity of the 
placental syncytiotrophoblasts in PE which would trigger the generation of anti-apoptotic 
proteins in an attempt to counteract pro-inflammatory molecules such that homeostasis 
is achieved. 
Peroxiredoxins are a family of proteins involved in the metabolism of reactive oxygen 
species. Peroxiredoxins function as a scavenger for H2O2 and contribute to cellular 
protection against H2O2-induced cell damage and apoptosis (Berggren et al., 2001). In 
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our study, we found upregulation of Peroxiredoxin-6 in PE STBM (7-fold change, 
p<0.05). An increased expression of this group of proteins may be explained as a 
response to counteract the existing oxidative stress in PE and RM.  
Clathrin mediates sorting of cell membrane cargo and recruitment of lipid modifiers 
(Brodsky et al., 2012). We found upregulation of clathrin in RM STBM (3-fold change, 
p<0.05). Components of glycolytic pathways such as glyceraldehyde-3-phosphate 
dehydrogenase was expressed, having important functional relevance in anaerobic 
glycolysis in trophoblasts enriched in glycogen. Weak expressions of various 
procoagulant complement components as well as complement regulatory proteins such 
as C1q, C3, C4, CD46, CD55 and CD59 were also found, suggestive of possible role of 
STBM in hemostatic activation as well as regulation. Two recently described proteins in 
PE sera, chorionic somatomammotropin hormone (CSH) secreted by placental 
syncytiotrophoblast and fibulin were also found in our study (Liu et al., 2011). CSH have 
a role in lypolysis and may contribute towards dyslipidemia of PE (Muraj et al., 1997). 
Fibulin as well as protein S100-A11 are involved in ECM remodeling. We found 
upregulation of protein S100-A11 in PE STBM (3-fold change, p<0.05). This expression 
in STBM may be suggestive of tissue injury, endothelial damage, ischaemia and hypoxia 
in adverse pregnancies (Redfern et al., 2000). Collectively all these protein expressions 
possibly depict the syncytiotrophoblast response at maternal-fetal interphase to 
underlying pregnancy pathology in PE and RM. 
Integrin signaling (including ligands for fibronectin) has important role in trophoblast 
invasion and vasculature remodeling (Huppertz et al., 2012). Its downregulation in PE 
STBM (0.04-fold change, p<0.05) may be associated with shallow trophoblast invasion 
and defective placental vasculature in PE and RM. The fibrinogens are involved in 
coagulation and their upregulation may be associated with the pro-coagulant state of PE 
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and RM. Fibrinogen, in association with fibronectin, is known to have an important role in 
extracellular matrix (ECM) remodeling (Mosesson et al., 2005). Fibronectin is also 
known to have an important role in trophoblast differentiation (Benoit et al., 2007). 
Increased expression of these proteins, as found in RM STBM in the present study, may 
represent a protective response to tissue injury in pathologic pregnancies. Fibronectin is 
already considered a promising biomarker to predict PE (Leeflang et al., 2007) and it 
would be interesting to investigate further its biomarker potential in prediction of RM. 
Major functions of histones include DNA binding, DNA repair and transcriptional 
regulation (Liang et al., 2012). The unique finding of downregulation of histones in both 
PE and RM STBM in this study (0.3-and 0.4-fold change, respectively, p<0.05) may be 
suggestive of defective DNA repair, increase in damaged DNA and raised inflammatory 
response in adverse pregnancies. 
Interestingly, we found that STBM proteins include endogenous danger molecules or 
alarmins which may render them intensely pro-inflammatory such as extracellular free 
actin, S100, fibronectin, transthyretin, besides heat shock proteins (Redman et al., 
2012). This supports the currently emerging role of STBM as contributors to the pro-
inflammatory state of PE and RM. 
We acknowledge the small number of observations as a significant weakness of this 
study and that our findings are preliminary. Due to constraints of resources, sample 
number could not be increased. However, this number gives us sufficient statistical 
power. Future biomarker discovery work will include STBM proteomic analysis of higher 
number of placentas from more severe phenotypes of RM and PE and validation of 
biomarker potentials of differentially expressed proteins in patients’ plasma. We also 
acknowledge the limitations of using label-free method and spectral counts in 
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demonstrating the true representation of differential expression of low abundance 
proteins. Confirmation of some of the differentially expressed proteins needs to be 
carried out with isotope-encoded peptides corresponding to the tryptic peptides of the 
selected proteins. This will help determine absolute concentration of targeted proteins.  
Immunohistochemistry was performed on placenta instead of Western analysis of STBM 
proteins, due to sample constraints. Furthermore, there are limitations of using label-free 
method and spectral counts in demonstrating the true representation of differential 
expression of low abundance proteins. Confirmation of some of the differentially 
expressed proteins needs to be carried out with isotope-encoded peptides 
corresponding to the tryptic peptides of the selected proteins. This will help determine 
absolute concentration of targeted proteins.  
Immunohistochemistry was performed on placenta instead of STBM. The protein effects 
observed in STBM analyzed by LC-MS/MS diluted out as immunohistochemical staining 
intensities were measured in syncytiotrophoblast layer of placental sections. Compared 
to the parent cell syncytiotrophoblast, STBM is likely to be enriched in a variety of 
signaling proteins, similar to other microvesicle populations. This may explain the 
upregulation of certain proteins relevant to pathologic pregnancies observed in STBM 
but not in placenta. 
In conclusion, the present study shows the main biological pathways associated with PE 
and RM include inflammation, coagulation, endothelial dysfunction and lipid metabolism. 
While previous evidence for increased activation of hemostasis and endothelial 
dysfunction exists, the concept and proposed roles of immune-dysregulation and lipid 
metabolism in pathophysiology of adverse pregnancies are novel and yet to be 
established. Our findings are consistent with recent reports on PE pregnancy sera     
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(Blumenstein et al., 2009, Liu et al., 2011), demonstrating pro-inflammatory and lipid-
regulatory protein expression, besides those involved in hemostasis and endothelial 
dysfunction. Targeting these novel pathways may offer newer strategies of management 
of adverse pregnancies. 
7.3  Lipidomic Analysis of Human Placental STBM in Adverse 
Pregnancy Outcomes 
 
Dysregulated lipid metabolism is currently emerging among the key pathogenetic 
pathways implicated in adverse pregnancy outcomes such as PE and RM. Recent 
reports on proteomic analysis of plasma from pre-eclampsia patients show presence and 
differential expression of lipid metabolism-related proteins which may lead to protein-lipid 
interactions including annexins and clotting proteins, e.g. fibrinogens related to PS, 
apolipoproteins related to cholesterols and triacylglycerides (TAG), and serum amyloid 
proteins A2 and A4 related to cholesterols (Blumenstein et al., 2009, Liu et al., 2011). It 
is also known that TNF-α and other proinflammatory cytokines which are upregulated in 
PE and RM, mediate lipid dysregulation in adverse pregnancies by inducing insulin 
resistance, inhibiting lipogenesis, stimulating lypolysis and releasing FFA in maternal 
circulation.  
To date most published reports on dyslipidemia of PE have focused on plasma level of 
lipid peroxides, cholesterols and TAG (Bayhan et al., 2000, Barden et al., 2001, Adiga et 
al., 2007, Lima et al., 2011, Ahmedi et al, 2012, Gohil et al, 2012).  However, knowledge 
on other polar lipids, e.g. sphingolipids and glycerophospholipids is lacking. These major 
membrane lipids form precursors for second messengers and functional assembly 
matrices on membrane domains during cellular stimulation and signaling (Fernandis et 
al., 2007). This present study investigated lipid profiles of placental microvcesicle STBM 
shed from syncytiotrophoblast membrane, with a focus on phospholipids and 
sphingolipids. We separated and quantified various polar lipids in placental STBM using 
ESI LC MS MRM approach. To our knowledge this study is the first report of STBM 
lipidome in PE and RM in comparison to that of normal healthy pregnancies.  
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Our results showed that in STBM, the most abundant polar lipid is SM (up to 35%), 
followed by PS, PA, PC and PI. A previous report on lipidomic analysis of microvesicles 
derived from human B cells similarly showed an enrichment of SM, beside GM3 and 
cholesterol (Wubblots et al., 2003). We also observed a unique reversal of SM/PC ratio 
(3:1) contrary to that in normal human cells. Although similar trend of SM/PC ratio was 
observed between patients with successful pregnancy outcomes and normal control 
groups, the ratio showed marked difference between an RM patient with ongoing 
pregnancy loss (SM:PC, 30%:13%) and her gestational age-matched normal control 
(SM:PC, 20%:12%). SM is known to be involved in various biological pathways such as 
inflammation, immune response, and oxidative stress (Lahiri et al., 2007), which are 
likely to be upregulated in active RM with an ongoing pregnancy loss.  This may explain 
the observed upregulation of SM in active RM compared to the control. Besides, 
selective incorporation of biologically active components including lipids are known 
phenomenon in microvesicle biogenesis and their role as vehicles of intercellular 
signaling may have necessitated an enrichment of SM.  
Recently aberrant expressions of sphingolipids including gangliosides resulting in 
disorganizations of membrane microdomains have been implicated in pathogenesis of 
metabolic disorders, e.g. type 2 diabetes, which also involves oxidative stress (Inokuchi 
et al., 2009). Thus significantly elevated levels of few SM species and decreased levels 
of some GM3 species in STBM from adverse pregnancies, as observed in the present 
study, may also be relevant in pathogenesis of complicated pregnancies. 
We also observed significant upregulation of total levels of PS and downregulation of PI, 
PA and GM3 in preeclampsia and similar trends in RM, compared to healthy pregnant 
controls. This might have implications in pathogenesis of preeclampsia. Also, STBM 
lipids may be relevant in a subset of idiopathic RM with increased number of circulating 
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procoagulant microvesicles and this may be of interest to investigate further in the future. 
Laude and coworkers reported this population to be 59% in patients with early losses 
(<10 gestational weeks) and  48% in patients with late losses (> 10 weeks) (Laude et al., 
2001). PS is among important signaling molecules involved in coagulation and apoptosis 
(Leventis et al., 2010) and these pathways are known to be exaggerated in 
preeclampsia and RM (Li et al., 2009, Cindrova-Davies et al., 2009), possibly mediated 
by placenta-derived factors such as reactive oxygen species (ROS). ROS activate 
various stress pathways, including proapoptotic p38 and SAPK/JNK MAPK pathways 
and inflammatory NF-kB pathway These pathways promote increased shedding of 
microvesicles, anti-angionenic factors and inflammatory cytokines, as well as initiates 
the blood coagulation cascade. 
Thus an elevated expression of PS in STBM could be reflective of activation of apoptotic 
pathways in placental trophoblast in adverse pregnancies. PI and PA are involved in 
regulation of apoptosis, proliferation and differentiation (Kabayama et al., 2007) and their 
downregulation may represent a protective response against placenta-derived pro-
apoptotic stressors such that homeostasis is achieved. Interestingly, in the RM group, 
levels of PS and PI changed significantly with number of losses and heparin treatment. It 
is suggested that heparin may be beneficial in RM by exerting protection against 
trophoblast apoptosis, pro-angiogenic, anti-inflammatory, and anti-coagulant effects 
(Matthiesen et al., 2012). The possible role of heparin in correction of dyslipidemia in RM 
may be of interest to investigate further in the future. Sphingolipids including ganglioside 
GM3 are important signaling molecules in immune response, inflammation and oxidative 
stress pathways (Corda et al., 2002, Kabayama et al., 2007, Paccalet et al., 2010). GM3 
downregulation as noted in the present study could be a response to the state of 
increased inflammatory and oxidative stress known to exist in adverse pregnancies.  
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Cholesterol is an essential mammalian cell membrane component (Simons et al., 2002). 
Aberrant levels of sterol lipids are known to be associated with coronary heart disease, 
stroke, and diabetes (Simons et al., 2002, Kingsbury et al, 1969, Gross et al., 2007). 7β-
OHC and 7-KC are formed as a result of cholesterol oxidation and serve as biomarkers 
for oxidative stress in atherosclerosis and other diseases (Witztum et al., 1994, Larsson 
et al., 2007, Lee et al., 2009)). In the present study, cholesterol and CE, showed a trend 
towards increase in STBM from adverse pregnancies compared to that from healthy 
pregnancies, while 24-OHC and 7-OHC showed a trend towards decrease in 
preeclampsia and RM. 24-OHC and 7-OHC have regulatory roles in cholesterol 
homeostasis and elimination of cholesterol. Their decreased expression as observed in 
diseased STBM in our study could be associated with the lipid dysregulation, elevated 
free cholesterols as well as cholesteryl esters, in these immune-dysregulated 
pregnancies.  
We observed substantial changes in the polyunsaturated species in PI and PS, with 
those in the former class being significantly decreased and those in the latter being 
significantly increased in both preeclampsia and RM patients compared to controls. This 
may imply that there is a preference for PS over PI synthesis in patients. Both PS and PI 
synthesis involve the same substrate (CDP-diacylglycerol or CDP-DAG) (KEGG 
pathway database for glycerophospholipid metabolism). There is probably an 
upregulation of PS synthesizing enzyme, PS synthase, and a downregulation of PI 
synthesizing enzyme (CDP-DAG-inositol-3-phosphatidyltransferase) in patients that led 
to the observed lipid metabolite differences. Hence, future work can be carried out to 
establish the enzyme activities in these patients. 
In conclusion the present study suggests that the biological pathways associated with 
preeclampsia and RM may include lipid metabolism. Further studies are required to 
investigate the roles of differentially expressed lipids in STBM from preeclampsia and 
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RM patients as potential biomarkers in peripheral blood plasma for detection of onset of 
these adverse pregnancies. While previous evidence for increased activation of immune-
response and haemostasis as well as endothelial dysfunction exists, the concept and 
proposed roles of lipid metabolism in pathophysiology of adverse pregnancies is novel 
and yet to be established. Targeting these novel pathways may offer newer strategies of 
management of adverse pregnancies. 
7.4  Dendritic Cell Subsets Analysis in Human Decidua Shows 
 Presence of CD141hi DCs  
This study is the first report of the DC subsets in decidua from normal pregnant subjects 
and RM patients. Within the HLA-DR+lineage_CD14_ fraction of leukocytes we found a 
discrete human DC subset identified by high CD141 and low-to intermediate CD11c 
expression, recently reported to be isolated from skin, lung, and liver (Haniffa et al, 
2012). The authors found that skin CD141hi DCs are proliferating and include a subset 
of immature cells related to but distinct from blood CD141+ DCs, suggesting that they 
are potentially derived from CD141+ blood DCs. In vitro CD141hi DCs were the most 
efficient antigen presenting cells compared to other interstitial DCs. These cells produce 
very little IL-12 and IL-23 when stimulated but produce CXCL10 and TNF-α. CXCL10 
and XCL1 form a chemokine circuit between DCs expressing XCR1 and activated NK 
cells or Th1 cells (Dorner et al., 2009; Crozat et al., 2010; Contreras et al., 2010). In 
addition to CD141hi DCs, human decidua contains CD11c+ DCs and CD14+ DCs, as 
previously described, notably in the skin (Lenz et al., 1993; Nestle et al., 1993; Haniffa et 
al., 2009). A recent study isolated CD 141+ DCs from human skin which also produce   
IL-10, and induce regulatory T cells (Chu et al., 2012). Haniffa et al argued this 
population of CD 141+ DCs isolated by Chu and colleagues corresponds to CD14+ DCs 
which the former found to have similar phenotype and function. 
CD141+ dermal DCs were found to possess lymph node migratory capacity, induce T 
cell hyporesponsiveness, cross-present self-antigens to autoreactive T cells, and induce 
potent regulatory T cells that inhibit skin inflammation. These CD141+ dermal DC-like 
cells can be generated in vitro and, once transferred in vivo, have the capacity to inhibit 
xeno-graft versus host disease and tumor alloimmunity. These findings suggest that 
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CD141+ dermal DCs play an essential role in the maintenance of skin homeostasis and 
in the regulation of both systemic and tumor alloimmunity. 
Likewise, CD14+CD141+ DCs could be relevant at maternal-fetal interface and may play 
an important role in maintenance of tolerance leading to a normal healthy pregnancy 
outcome. It would be interesting to study distribution of these cells in adverse 
pregnancies associated with immunedysregulation e.g. RM which has been shown to be 
associated with increased number of IL-17+ T cells as well as reduced numbers and 
function of Foxp3+ regulatory T cells (Treg) in peripheral blood (Lee et al., 2011) and 
increased proportion of Th17 cells in peripheral blood and deciduas (Wang et al., 2010). 
Various factors including GM-CSF regulates the efficiency with which uterine DCs and 
macrophages activate T cells, and it is essential for optimal MHC class II- and class I-
mediated indirect presentation of reproductive antigens. Insufficient GM-CSF may impair 
generation of T cell-mediated immune tolerance at the outset of pregnancy and may 
contribute to the altered DC profile and dysregulated T cell tolerance evident in RM 
(Moldenhauer et al., 2010). 
Enhanced pro-inflammatory immune responses with suppressed immune regulation is 
considered an important immune mechanism involved in RM and a reduced number of 
CD14+CD141+ DCs could reflect maternal immune maladaptation to the foetus in RM. 
We found a considerably high frequency of CD141hi DCs in the decidua of a treated RM 
patient with a history of 5 recurrent miscarriages and subsequent successful pregnancy 
outcome. We speculate CD141hi DCs could be the population capable of most efficient 
cross-presentation of soluble fetal antigens to maternal T cells, production of TNF-α and 
induction of CTL responses. Intervention or treatment may have dampened the 
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stimulatory function of these cells and this immunosuppression could have facilitated a 
healthy pregnancy outcome.  
This component of the PhD is an ongoing study and our findings on decidual DC subsets 
would need further validation in a larger group of RM patients. Our findings may aid 
development of novel strategies for diagnosis and treatment of immune-dysregulation in 
adverse pregnancies.  
 
 7.5 Conclusions 
Placental syncytiotrophoblast microvesicles (STBM) are biologically active, membrane-
bound, subcellular vesicles shed into maternal circulation during pregnancy as a normal 
turnover of the placental surface. They interact with maternal immune cells and vascular 
endothelium in intervillous space and uterine decidua. A successful feto-maternal cross-
talk is considered pivotal in immunomodulation of normal pregnancy leading to the 
acceptance of the feto-placental semi-allograft. Quantitative and possibly qualitative 
STBM changes take place in adverse pregnancy outcomes such as pre-eclampsia (PE). 
However, the role of STBM in recurrent miscarriage (RM) remains insufficiently explored.  
The study objectives were to evaluate the immunogenicity of STBM in women with RM 
by investigating whether i) STBM stimulate antigen presenting cells (APCs), e.g. 
dendritic cells (DCs) & macrophages more in disease compared to health; ii) STBM 
bioactive contents, e.g. proteins and lipids, differ in disease and health; and iii) decidual 
DCs involved in fetal antigen presentation to T cells at maternal-fetal interface differ in 
disease and health. 
STBM from RM and PE patients demonstrated significantly increased immunogenicity, 
causing significantly increased production of proinflammatory cytokines, e.g. IL-6  and 
TNF-α from DCs, compared to STBM from gestational age-matched healthy pregnant 
women.  
Next, to understand the factors attributing to the immunogenicity of STBM, we 
investigated STBM protein and lipid composition. Among the STBM proteins, 14 were 
found to be differentially expressed in STBM derived from women with PE and RM 
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compared to healthy controls. Notable among these proteins were annexins, histones, 
integrins, fibrinogens, fibronectin, peroxiredoxins, clathrin and protein S-100 A11, all of 
which were upregulated with the interesting exception of histones.  
Lipidomic analysis revealed that the major lipid classes in STBM are sphingomyelin 
(SM), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidic acid (PA), and 
phosphatidylinositol (PI). SM/PC ratio showed a unique reversal (3:1) compared to that 
normally found in human cells. PS was upregulated and PI, PA and GM3 was 
downregulated in adverse pregnancies compared to healthy pregnant controls. 
Collectively, differential expressions of STBM proteins and lipids in RM and PE could be 
observed. These proteins and lipids have been implicated in inflammation, coagulation, 
oxidative stress, apoptosis and immune response, suggesting a pathophysiologic 
relevance of STBM in adverse pregnancy outcomes. The observed qualitative changes 
in STBM possibly represent homeostatic responses by the syncytiotroblast positioned at 
maternal-fetal interface. 
Finally, to investigate the in vivo decidual DC population, we analyzed dendritic cell 
subsets. Significant findings include the presence of CD141hi DCs which has been 
recently reported to be the most efficient antigen presenting cell in human peripheral 
tissues (Haniffa et al., 2012). One particular patient with 5 previous miscarriages 
demonstrated a markedly higher frequency of CD141hi DCs (1.48% of CD45+ cells), 
compared to the other RM (0.2%) and the normal controls (0.2%). This study is ongoing 
and validation of present findings would be required in a larger group of patients. 
Nevertheless, I would like to speculate that CD141hi DCs may contribute locally to 
maternal-foetal immune maladaptation in PE and RM. 
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In summary, the findings of this study lend support to the emerging concept of immune-
dysregulation in adverse pregnancy outcomes. This in turn has implications in 
development of novel approaches of diagnosis and therapy of these significant yet 
perplexing, unresolved clinical problems.  
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7.6 Limitations of current study and future works 
In the present study, the number of study subjects in RM with non-live birth group is 
small. We acknowledge that data from pregnant patients with history of RM who 
subsequently miscarry would be of great interest to the scientific community and 
contribute towards better understanding of pathogenesis of RM. Recruitment of patients 
to obtain higher number of cases in this group and analysis is ongoing and we hope to 
publish this data in future. 
Peripheral blood leukocytes from healthy non-pregnant donors, in the form of buffy coat, 
were used in this study to generate antigen presenting cells (APCs), DCs and 
macrophages. Autologous source of peripheral blood leukocytes (matched maternal 
blood) would have probably increased the cytokine signals elicited in stimulation assays; 
as during pregnancy, monocytes are known to be primed to produce pro-inflammatory 
cytokines (Germain et al., 2007). Currently matched maternal monocytes are being 
stored and will be tested in DC stimulation assays in future.  
Placental explant culture was used in this study to generate STBM (eSTBM) as it 
remains the simplest method to generate STBM in large number. However, STBM 
generated by perfusion of placental cotyledon (pSTBM) is known to be superior to 
eSTBM with regard to immunogenicity (Messerli et al., 2010). In addition, the use of a 
cell culture system to generate STBM will also introduce artefacts from cell types other 
than trophoblasts (such as fibroblasts, endothelial cells, blood cells from foetal blood 
vessels in placental villi) into the system. Using pSTBM probably would have resulted in 
better stimulation of APCs. In future, pSTBM generation system will be established and 
used for further experiments. 
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The data on DC stimulation by STBM were derived in vitro. A better model could have 
been in vivo animal model such as abortion-prone mouse model or humanized mouse 
model. 
For STBM proteomic analysis, label-free method and spectral counts were applied, 
which have limitations in demonstrating the true representation of differential expression 
of low abundance proteins. Confirmation of some of the differentially expressed proteins 
needs to be carried out with isotope-encoded peptides corresponding to the tryptic 
peptides of the selected proteins. This will help determine absolute concentration of 
targeted proteins.  
Immunohistochemistry was performed on placenta instead of on STBM due to sample 
constraints. The protein effects observed in STBM analyzed by LC-MS/MS diluted out as 
immunohistochemical staining intensities were measured in syncytiotrophoblast layer of 
placental sections, instead of on STBM. A labelled method to determine absolute 
concentration of targeted proteins in STBM will be carried out in future. Also, synthetic 
microvesicles could be used as vectors for specific proteins or lipids to test their 
immunogenic potential in an animal model. 
Decidual DC subset analysis is an ongoing study and our findings on decidual DC 
subsets would need further validation in a larger group of RM patients.  
Notwithstanding these limitations, our study offers an insight into the pathophysiologic 
relevance of STBM in RM and provides a foundation for further elaborate research into 
the pathogenesis of RM.  
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